Professor Janet Dunn is Head of Cancer Trials at Warwick Clinical Trials Unit (CTU) at Warwick Medical School, University of Warwick. She has over 30 years clinical trials experience. She qualified with a BSc (2i) in Mathematical Sciences in 1987, an MSc in Applied Statistics in 1989 from Manchester and gained a PhD in Medicine in 2004 from Birmingham. She started as a junior statistician in 1988 at the Cancer Research UK Clinical Trials Unit, University of Birmingham, working up to Deputy Director and then Assistant Director responsible for over 25 phase III multi-centre randomised clinical trials. She was instrumental in establishing Birmingham as one of the initial 6 national accredited cancer clinical trials units. In 2003 she was awarded a USA National Cancer Institute fellowship which involved a 6 month sabbatical at Washington DC assessing smoking as a risk factor for pancreatic cancer. She is involved in National Cancer Research Institute (NCRI) breast, colorectal, pancreatic, myeloma, melanoma, and head & neck cancer trials and is currently on the NCRI breast cancer clinical studies group. In January 2006 she was appointed as Professor of Clinical Trials and head of cancer trials at Warwick CTU and was instrumental in establishing cancer trials. Warwick CTU gained full UKCRN registration in 2008 and moved into their new building in 2009 having secured money from Advantage West Midlands Science City and the Wolfson Foundation. Her research interests include the evaluation of prognostic and predictive factors in cancer clinical trials, and designing clinical trials to impact on clinical practice. The establishment of the National Cancer Research Network and the continued funding from Cancer Research UK has resulted in the completion of many successful UK academic trials which have challenged and changed clinical practice. In 2008 Professor Dunn was awarded National Institute of Health Research Senior Investigator status being one of the inaugural cohort of investigators contributing to applied patient centred research. She has been successful in attracting NIHR National Coordinating Centre for Health Technology Assessment (NCCHTA) grants totalling £6 million for cancer trials at Warwick. These achievements have resulted in Warwick CTU being one of the 15 NCRI badged CTUs demonstrating esteem for the Cancer trials carried out within Warwick CTU.
- Azam, Ayesha S., Tsang, Yee?Wah, Thirlwall, Jenny, Kimani, Peter K., Sah, Shatrughan, Gopalakrishnan, Kishore, Boyd, Clinton, Loughrey, Maurice B., Kelly, Paul J., Boyle, David P., Salto?Tellez, Manuel, Clark, David, Ellis, Ian O., Ilyas, Mohammad, Rakha, Emad, Bickers, Adam, Roberts, Ian S. D., Soares, Maria F., Neil, Desley A. H., Takyi, Abi et al (Select to open full list), 2024. Digital pathology for reporting histopathology samples, including cancer screening samples ? definitive evidence from a multisite study. Histopathology
- Bowcock, Stella, Atkin, Catherine, Iqbal, Gulnaz, Pratt, Guy, Yong, Kwee, Neal, Richard D., Planche, Tim, Karunanithi, Kamaraj, Jenkins, Stephen, Stern, Simon, Arnott, Sarah, Toth, Peter, Wandroo, Farooq, Dunn, Janet A., Drayson, Mark T., 2023. Presenting symptoms in newly diagnosed myeloma, relation to organ damage, and implications for symptom-directed screening : a secondary analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) trial. Cancers, 15 (13)
- 'Yao, C., 'Osdoit, M., 'van der Noordaa, M., 'Shad, S., 'Wei, J., 'de Croze, D., 'Hamy, A -S., 'La?, M., 'Reyal, F., 'Sonke, G. S., 'Steenbruggen, T. G., 'van Seijen, M., 'Wesseling, J., 'Mart?n, M., 'del Monte-Mill?n, M., 'L?pez-Tarruella, S., 'Boughey, J. C., 'Goetz, M. P., 'Hoskin, T., 'Gould, R. et al (Select to open full list), 2022. 'Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer : a multicentre pooled analysis of 5161 patients. Lancet Oncology, 23 (1), pp. 149-160
- 'Rischin, D., 'Mehanna, H., 'Young, R. J., 'Bressel, M., 'Dunn, Janet A., 'Corry, J., 'Soni, P., 'Fulton-Lieuw, T., 'Iqbal, G., 'Kenny, L., 'Porceddu, S., 'Wratten, C., 'Robinson, M., 'Solomon, B. J., 2022. 'Prognostic stratification of HPV-associated oropharyngeal cancer based on CD103+ immune cell abundance in patients treated on TROG 12.01 and De-ESCALaTE randomized trials. Annals of Oncology, 33 (8), pp. 804-813
- Sammut, S., Crispin-Ortuzar, M., Chin, S. F., Provenzano, E., Bardwell, H. A., Ma, W., Cope, W., Dariush, A., Dawson, S. J., Abraham, J., Dunn, Janet A., Hiller, Louise, Thomas, J., Cameron, D. A., Bartlett, John M. S., Hayward, Larry, Pharoah, Paul D., Markowetz, Florian, Rueda, Oscar M., Earl, Helena M. et al (Select to open full list), 2022. Multi-omic machine learning predictor of breast cancer therapy response. Nature, 601, pp. 623-629
- Agbuduwe, Charles, Iqbal, Gulnaz, Cairns, David, Menzies, Tom, Dunn, Janet A., Gregory, Walter, Kaiser, Martin, Owen, Roger, Pawlyn, Charlotte, Child, J. Anthony, Davies, Faith, Morgan, Gareth J., Jackson, Graham H., Drayson, Mark T., Basu, Supratik, 2022. Clinical characteristics and outcomes of IgD myeloma : experience across UK national trials. Blood Advances, 6 (17), pp. 5113-5123
- Goyal, Amit, Puri, Shama, Marshall, Andrea, Valassiadou, Kalliope, Hoosein, Moin M., Carmichael, Amtul R., Erdelyi, Gabriella, Sharma, Nisha, Dunn, Janet A., York, Joanne, 2021. A multicentre prospective feasibility study of carbon dye tattooing of biopsied axillary node and surgical localisation in breast cancer patients. Breast Cancer Research and Treatment, 185, pp. 433-440
- Geach, R., Jones, L. I., Harding, S. A., Marshall, A. (Andrea), Taylor-Phillips, Sian, McKeown-Keegan, S., Dunn, Janet A., 2021. The potential utility of abbreviated breast MRI (FAST MRI) as a tool for breast cancer screening : a systematic review and meta-analysis. Clinical Radiology, 76 (2), pp. 154.e11-154.e22
- Earl, Helena M., Hiller, Louise, Dunn, Janet A., Macpherson, Iain, Rea, Daniel, Hughes-Davies, Luke, McAdam, Karen, Hall, Peter, Mansi, Janine, Wheatley, Duncan, Abraham, Jean, Caldas, Carlos, Gasson, Sophie, O'Riordan, Liz, Wilcox, Maggie, Miles, David, Cameron , David, Wardley, Andrew, 2021. Optimising the duration of adjuvant trastuzumab in early breast cancer in the UK. Clinical Oncology, 33 (1), pp. 15-19
- Kosmin, Michael, Padhani, Anwar R., Gogbashian, Andrew, Woolf, David, Ah-See, Mei-Lin, Ostler, Peter, Sutherland, Stephanie, Miles, David, Noble, Jillian, Koh, Dow-Mu, Marshall, Andrea, Dunn, Janet A., Makris, Andreas, 2020. Comparison of whole-body MRI, CT, and bone scintigraphy for response evaluation of cancer therapeutics in metastatic breast cancer to bone. Radiology, 297 (3), pp. 622-629
- Conefrey, C., Donovan, J. L., Stein, R. C., Paramasivan, S., Marshall, Andrea, Bartlett, J., Cameron, D. A., Campbell, Amy, Dunn, Janet A., Earl, H., Hall, P., Harmer, V., Hughes-Davies, L., Macpherson, I., Makris, A., Morgan, A., Pinder, S. E., Poole, Christopher J., Rea, D., Rooshenas, L., 2020. Strategies to improve recruitment to a de-escalation trial : a mixed-methods study of the OPTIMA prelim trial in early breast cancer. Clinical Oncology
- Jones, David A., Mistry, Pankaj, Dalby, Matthew, Fulton-Lieuw, Tessa, Kong, Anthony H., Dunn, Janet A., Mehanna, Hisham M., Gray, Alastair M., 2020. Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer : Medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial. European Journal of Cancer Care, 124, pp. 178-185
- Earl, Helena, Hiller, Louise, Vallier, Anne-Laure, Loi, Shrushma, McAdam, Karen, Hughes-Davies, Luke, Rea, Daniel, Howe, Donna L., Raynes, Kerry, Higgins, Helen B., Wilcox, Maggie, Plummer, Chris, Mahler-Araujo, Betania, Provenzano, Elena, Chhabra, Anita, Gasson, Sophie, Balmer, Claire E., Abraham, Jean E., Caldas, Carlos, Hall, Peter et al (Select to open full list), 2020. Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer : the PERSEPHONE non-inferiority RCT. Health Technology Assessment, 24 (40), pp. 1-190
- Marshall, Andrea, Levine, Mark, Hill, Catherine, Hale, Danielle, Thirlwall, Jenny, Wilkie, Veronica, French, Karen, Kakkar, Ajay K., Lokare, Anand, Maraveyas, Anthony, Chapman, Oliver, Arif, Azra, Petrou, Stavros, Maredza, Mandy, Hobbs, FD Richard, Dunn, Janet A., Young, Annie M., 2020. Treatment of cancer-associated venous thromboembolism : 12-month outcomes of the placebo versus rivaroxaban randomisation of the SELECT-D Trial. (SELECT-D: 12m). Journal of Thrombosis and Haemostasis, 18 (4), pp. 905-915
- Fernando, Indrajit N., Bowden, Sarah J., Herring, Kathryn, Brookes, Cassandra L., Ahmed, Ikhlaaq, Marshall, Andrea, Grieve, Robert J., Churn, Mark, Spooner, David, Latief, Talaat N., Agrawal, Rajiv K., Brunt, Adrian M., Stevens, Andrea, Goodman, Andrew, Canney, Peter, Bishop, Jill, Ritchie, Diana, Dunn, Janet A., Poole, Christopher J., Rea, Daniel W., 2020. Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB) : a randomised, phase III, trial. Radiotherapy and Oncology, 142, pp. 52-61
- Bartlett, John M. S., Bayani, Jane, Kornaga, Elizabeth N., Danaher, Patrick, Crozier, Cheryl, Piper, Tammy, Yao, Cindy Q., Dunn, Janet A., Boutros, Paul C., Stein, Robert C., 2020. Computational approaches to support comparative analysis of multiparametric tests : modelling versus training. PLOS ONE, 15 (9)
- Drayson, Mark T., Bowcock, Stella, Planche, Tim, Iqbal, Gulnaz, Pratt, Guy, Yong, Kwee, Wood, Jill, Raynes, Kerry, Higgins, Helen, Dawkins, Bryony, Meads, David, Hulme, Claire T., Whittaker, Anna C., Hawkey, Peter, Low, Eric, Dunn, Janet A., 2019. Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT. Health Technology Assessment, 23 (62), pp. 1-94
- Earl, Helena M., Hiller, Louise, Vallier, Anne-Laure, Loi, Shrushma, McAdam, Karen, Hughes-Davies, Luke, Harnett, Adrian N, Ah-See, Mei-Lin, Simcock, Richard, Rea, Daniel, Raj, Sanjay, Woodings, Pamela, Harries, Mark, Howe, Donna L., Raynes, Kerry, Higgins, Helen B., Wilcox, Maggie, Plummer, Chris, Mansi, Janine, Gounaris, Ioannis et al (Select to open full list), 2019. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE) : 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. The Lancet, 393 (10191), pp. 2599-2612
- Zarkar, A., Marshall, Andrea, Davies, A., Ford, D., James, N. D., Dunn, Janet A., 2019. Cabazitaxel in platinum pre-treated patients with locally advanced or metastatic transitional cell carcinoma who developed disease progression after platinum based chemotherapy : results of the phase II CAB-B1 trial. International Journal of Cancer Research & Therapy, 4 (4)
- Drayson, Mark T, Bowcock, Stella, Planche, Tim, Iqbal, Gulnaz, Pratt, Guy, Yong, Kwee, Wood, Jill, Raynes, Kerry, Higgins, Helen B., Dawkins, Bryony, Meads, David, Hulme, Claire T, Monahan, Irene, Karunanithi, Kamaraj, Dignum, Helen, Belsham, Edward, Neilson, Jeff, Harrison, Beth, Lokare, Anand, Campbell, Gavin et al (Select to open full list), 2019. Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM) : a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial.. The Lancet. Oncology, 20 (12), pp. 1760-1772
- Escala-Garcia, Maria, Guo, Qi, Dörk, Thilo, Canisius, Sander, Keeman, Renske, Dennis, Joe, Beesley, Jonathan, Lecarpentier, Julie, Bolla, Manjeet K., Wang, Qin, Abraham, Jean, Andrulis, Irene L., Anton-Culver, Hoda, Arndt, Volker, Auer, Paul L., Beckmann, Matthias W., Behrens, Sabine, Benitez, Javier, Bermisheva, Marina, Bernstein, Leslie et al (Select to open full list), 2019. Genome-wide association study of germline variants and breast cancer-specific mortality. British Journal of Cancer, 120 (6), pp. 647-657
- Dunn, Janet A., Jefferson, Kieran, MacDonald, Donald, Iqbal, Gulnaz, Bland, Rosemary, 2019. Low serum 25-hydroxyvitamin D is associated with increased bladder cancer risk: A systematic review and evidence of a potential mechanism. The Journal of Steroid Biochemistry and Molecular Biology, 188, pp. 134-140
- Jones, Lyn I., Geach, Rebecca, Harding, Sam A., Foy, Christopher, Taylor, Victoria, Marshall, Andrea, Taylor-Phillips, Sian, Dunn, Janet A., 2019. Can mammogram readers swiftly and effectively learn to interpret first post-contrast acquisition subtracted (FAST) MRI, a type of abbreviated breast MRI? : a single centre data-interpretation study. The British Journal of Radiology, 92
- Heaney, Jennifer L. J.,, Campbell, John P., Iqbal, Gulnaz, Cairns, David, Richter, Alex, Child, J. Anthony, Gregory, Walter, Jackson, Graham, Kaiser, Martin, Owen, Roger, Davies, Faith, Morgan, Gareth, Dunn, Janet A., Drayson, Mark T., 2018. Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials. Leukemia, 32, pp. 1727-1738
- Abdelrahim, Ameera, Balmer, Claire E., Jones, June, Mehanna, Hisham M., Dunn, Janet A., 2018. Considerations for a head and neck smoking cessation support programme ; a qualitative study of the challenges in quitting smoking after treatment for head and neck cancer. European Journal of Oncology Nursing, 35, pp. 54-61
- Heaney, Jennifer L. J., Campbell, John P., Iqbal, Gulnaz, Cairns, David, Richter, Alex, Child, J. Anthony, Gregory, Walter, Jackson, Graham, Kaiser, Martin, Owen, Roger, Davies, Faith, Morgan, Gareth, Dunn, Janet A., Drayson, Mark T., 2018. Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials. Leukemia, 32 (8), pp. 1727-1738
- Lin, Daniel J., McConkey, Christopher C., Nankivell, Paul, Dunn, Janet A., Mehanna, Hisham, 2018. The impact of institutional clinical trial recruitment versus hospital volume on survival outcomes of patients with head and neck cancer : an analysis of the PET-NECK trial outcomes, UKCRN portfolio, and Hospital Episode Statistics (HES) in England. Oral Oncology, 85, pp. 40-43
- Corrie, Pippa G., Marshall, A. (Andrea)?, Nathan, P D., Lorigan, P., Gore, M., Tahir, S., Faust, G., Kelly, C. G., Marples, M., Danson, S. J., Marshall, E., Houston, S. J., Board, R E., Waterston, A. M., Nobes, J. P., Harries, M., Kumar, S., Goodman, A., Dalgleish, A., Martin-Clavijo, A. et al (Select to open full list), 2018. Adjuvant bevacizumab for melanoma patients at high risk of recurrence : survival analysis of the AVAST-M trial. Annals of Oncology, 29 (8), pp. 1843-1852
- Lipplaa, Astrid, Fernandes, Ricardo, Marshall, Andrea, Lorigan, Paul, Dunn, Janet A., Myers, Kevin A, Barker, Emily, Newton-Bishop, Julia, Middleton, Mark R., Corrie, Pippa G., 2018. 25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial. British Journal of Cancer, 119, pp. 793-800
- Lee, R. J., Gremel, G., Marshall, A. (Andrea)?, Myers, K. A., Fisher, N., Dunn, Janet A., Dhomen, N., Corrie, P. G., Middleton, M. R., Lorigan, P., Marais, R., 2018. Circulating tumor DNA predicts survival in patients with resected high risk stage II/III melanoma. Annals of Oncology, 29 (2), pp. 490-496
- Fackrell, D., Marshall, A. (Andrea)?, Mistry, Pankaj, Dunn, Janet A., De Santis, Maria, Ford, D., Zarkar, A., 2018. Radical treatment of muscle-invasive bladder cancer-are options equal?. Journal of Radiation Oncology, 7 (2), pp. 181-186
- Hiller, Louise, Dunn, Janet A., Loi, Shrushma, Vallier, Anne-Laure, Howe, Donna L., Cameron, David A., Miles, David, Wardley, Andrew M., Earl, Helena M., 2018. Adjuvant trastuzumab duration trials in HER2 positive breast cancer : what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results. BMC Cancer, 18
- Taylor-Phillips, Sian, Jenkinson, David J., Stinton, Chris, Wallis, Matthew G., Dunn, Janet A., Clarke, Aileen, 2018. Double reading in breast cancer screening : cohort evaluation in the CO-OPS trial. Radiology, 287 (3), pp. 749-757
- Young, Annie M., Marshall, Andrea, Thirlwall, Jenny, Chapman, Oliver, Lokare, Anand, Hill, Catherine, Hale, Danielle, Dunn, Janet A., Lyman, Gary H., Hutchinson, Charles, MacCallum, Peter, Kakkar, Ajay, Hobbs, F. D. Richard, Petrou, Stavros, Dale, Jeremy, Poole, Christopher J., Maraveyas, Anthony, Levine, Mark, 2018. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in cancer patients with venous thromboembolism : results of a randomized trial (SELECT-D). Journal of Clinical Oncology, 36 (20), pp. 2017-2023
- Fenlon, D., Morgan, A., Khambaita, P., Mistry, Pankaj, Dunn, Janet A., Ah-See, M. L., Pennery, E., Hunter, M. S., 2017. Management of hot flushes in UK breast cancer patients : clinician and patient perspectives. Journal of Psychosomatic Obstetrics & Gynecology, 38 (4), pp. 276-283
- Mistry, Pankaj, Dunn, Janet A., Marshall, A. (Andrea), 2017. A literature review of applied adaptive design methodology within the field of oncology in randomised controlled trials and a proposed extension to the CONSORT guidelines. BMC Medical Research Methodology, 17 (1)
- Hall, P. S., Smith, A., Hulme, C., Vargas-Palacios, A., Makris, A., Hughes-Davies, L., Dunn, Janet A., Bartlett, J. M. S., Cameron, D. A., Marshall, A., Campbell, A., Macpherson, I. R., Dan, Rea, Francis, A., Earl, H., Morgan, A., Stein, R. C., McCabe, C., 2017. Value of information analysis of multiparameter tests for chemotherapy in early breast cancer : the OPTIMA prelim trial. Value in Health, 20 (10), pp. 1311-1318
- Ford, H., Marshall, A., Blazeby, J. M., Bridgewater, J. A., Wadsley, J., Coxon, F. Y., Mansoor, W., Madhusudan, S., Falk, S., Middleton, G. W., Swinson, D., Chau, I., Thompson, J., Cunningham, D., Kareclas, P., Dunn, Janet A., 2017. Cougar-02 : a randomized phase III study of docetaxel versus active symptom control in patients with relapsed esophago-gastric adenocarcinoma. Journal of Clinical Oncology, 31 (15)
- Earl, H. M., Hiller, Louise, Dunn, Janet A., Blenkinsop, C., Grybowicz, L., Vallier, A.-L., Gounaris, I., Abraham, J. E., Hughes-Davies, L., McAdam, K., Chan, S., Ahmad, R., Hickish, T., Rea, D., Caldas, C., Bartlett, J. M. S., Cameron, D. A., Provenzano, E., Thomas, J., Hayward, R. L., 2017. Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer : ARTemis Trial. Annals of Oncology, 28 (8), pp. 1817-1824
- Smith, A. F., Hall, P. S., Hulme, C. T., Dunn, Janet A., McConkey, Christopher C., Rahman, J. K., McCabe, C., Mehanna, H., 2017. Cost-effectiveness analysis of PET-CT-guided management for locally advanced head and neck cancer. European Journal of Cancer, 85, pp. 6-14
- Ali, H. R., Dariush, A., Thomas, J., Provenzano, E., Dunn, Janet A., Hiller, Louise, Vallier, A.-L., Abraham, J., Piper, T., Bartlett, J. M. S., Cameron, D. A., Hayward, L., Brenton, J. D., Pharoah, P. D. P., Irwin, M. J., Walton, N. A., Earl, H. M., Caldas, C., 2017. Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer : secondary analysis of the ARTemis trial. Annals of Oncology, 28 (8), pp. 1832-1835
- Mehanna, H., McConkey, Christopher C., Rahman, J., Wong, W. L., Smith, A. F., Nutting, C., Hartley, A. G. J., Hall, P., Hulme, C., Patel, D., Von Zeidler, S. V., Robinson, M., Sanghera, B., Fresco, L., Dunn, Janet A., 2017. PET-NECK : a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography-computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technology Assessment, 21 (17), pp. 1-122
- Thomas, Jeremy St John, Provenzano, Elena, Hiller, Louise, Dunn, Janet A., Blenkinsop, Clare, Grybowicz, Louise, Vallier, Anne-Laure, Gounaris, Ioannis, Abraham, Jean, Hughes-Davies, Luke, McAdam, Karen, Chan, Stephen, Ahmad, Rizvana, Hickish, Tamas, Houston, Stephen, Rea, Daniel, Caldas, Carlos, Bartlett, John M. S., Cameron, David Allan, Hayward, Richard Laurence et al (Select to open full list), 2017. Central pathology review with two-stage quality assurance for pathological response after neoadjuvant chemotherapy in the ARTemis Trial. Modern Pathology, 30 (8), pp. 1069-1077
- Pinder, S. E., Campbell, Amy, Bartlett, J. M. S., Marshall, A. (Andrea)?, Allen, D., Falzon, M., Dunn, Janet A., Makris, A., Hughes-Davies, L., Stein, R. C., 2017. Discrepancies in central review re-testing of patients with ER-positive and HER2-negative breast cancer in the OPTIMA prelim randomised clinical trial. British Journal of Cancer, 116, pp. 859-863
- Earl, Helena M., Hiller, Louise, Howard, Helen C., Dunn, Janet A., Young, Jennie, Bowden, Sarah J., McDermaid, Michelle, Waterhouse, Anna K., Wilson, Gregory, Agrawal, Rajiv, O'Reilly, Susan, Bowman, Angela, Ritchie, Diana M., Goodman, Andrew, Hickish, Tamas, McAdam, Karen, Cameron, David, Dodwell, David, Rea, Daniel W., Caldas, Carlos et al (Select to open full list), 2017. Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo) : final 10-year follow-up of an open-label, randomised, phase 3 trial. The Lancet Oncology, 18 (6), pp. 755-769
- Meads, David M., Marshall, A. (Andrea)?, Hulme, Claire T., Dunn, Janet A., Ford, Hugo E. R., 2016. The cost effectiveness of docetaxel and active symptom control versus active symptom control alone for refractory oesophagogastric adenocarcinoma : economic analysis of the COUGAR-02 trial. PharmacoEconomics, 34 (1), pp. 33-42
- Dorling, L, Kar, Siddhartha, Michailidou, Kyriaki, Hiller, Louise, Vallier, Anne-Laure, Ingle, Susan, Hardy, Richard, Bowden, Sarah J., Dunn, Janet A., Twelves, Chris, Poole, Christopher J., Caldas, Carlos, Earl, Helena M., Pharoah, Paul D. P., Abraham, Jean E., 2016. The relationship between common genetic markers of breast cancer risk and chemotherapy-induced toxicity : a case-control study. PLoS One, 11 (7)
- Bartlett, John M. S., Bayani, Jane, Marshall, A. (Andrea)?, Dunn, Janet A., Campbell, Amy, Cunningham, Carrie, Sobol, Monika S., Hall, Peter S., Poole, Christopher J., Cameron, David A., Earl, Helena M., Rea, Daniel W., Macpherson, Iain R., Canney, Peter, Francis, Adele, McCabe, Christopher, Pinder, Sarah E., Hughes-Davies, Luke, Makris, Andreas, Stein, Robert C., 2016. Comparing breast cancer multiparameter tests in the OPTIMA Prelim Trial : no test is more equal than the others. Journal of the National Cancer Institute, 108 (9)
- Young, Annie M., Phillips, Jennifer, Hancocks, N. Helen, Hill, Catherine, Joshi, Neya, Marshall, A. (Andrea)?, Grumett, Joanne, Dunn, Janet A., Lokare, A., Chapman, O., 2016. OC-11 - Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Thrombosis Research, 140, pp. S172-S173
- Francis, Adele, Stein, Robert C., Marshall, A. (Andrea?), Rea, Daniel W., Cameron, David A., Macpherson, Iain R., Earl, Helena M., Poole, Christopher J., Hall, Peter S., Bartlett, John M. S., Rooshenas, Leila, Morgan, Adrienne, Harmer, Victoria, Donovan, Jenny, Hulme, Claire, McCabe, Christopher, Pinder, Sarah E., Hughes-Davies, Luke, Makris, Andreas, Dunn, Janet A., 2016. OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis) : A prospective trial to validate the predictive utility and cost-effectiveness of gene expression test-directed chemotherapy decisions. European Journal of Surgical Oncology (EJSO), 42 (5), pp. S9-S10
- Earl, Helena M, Vallier, Anne-Laure, Dunn, Janet A., Loi, Shrushma, Ogburn, Emma, McAdam, Karen, Hughes-Davies, Luke, Harnett, Adrian, Abraham, Jean, Wardley, Andrew, Cameron, David A, Miles, David, Gounaris, Ioannis, Plummer, Chris, Hiller, Louise, 2016. Trastuzumab-associated cardiac events in the Persephone trial. British Journal of Cancer, 115 (12), pp. 1462-1470
- Ali, H. Raza, Dariush, Aliakbar, Provenzano, Elena, Bardwell, Helen, Abraham, Jean E., Iddawela, Mahesh, Vallier, Anne-Laure, Hiller, Louise, Dunn, Janet A., Bowden, Sarah J., Hickish, Tamas, McAdam, Karen, Houston, Stephen, Irwin, Mike J., Pharoah, Paul D. P., Brenton, James D., Walton, Nicholas A., Earl, Helena M., Caldas, Carlos, 2016. Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer. Breast Cancer Research, 18 (1)
- Janowitz, Tobias, Thuss-Patience, Peter, Marshall, A. (Andrea)?, Kang, Jung Hun, Connell, Claire, Cook, Natalie, Dunn, Janet A., Park, Se Hoon, Ford, Hugo, 2016. Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma : a meta-analysis of patient-level data. British Journal of Cancer, 114 (4), pp. 381-387
- Stein, Robert C., Dunn, Janet A., Bartlett, John M. S., Campbell, Amy, Marshall, A. (Andrea)?, Hall, Peter, Rooshenas, Leila, Morgan, Adrienne, Poole, Christopher, Pinder, Sarah E., Cameron, David A., Stallard, Nigel, Donovan, Jenny L., McCabe, Christopher, Hughes-Davies, Luke, Makris, Andreas, 2016. R : OPTIMA prelim : a randomised feasibility study of personalised care in the treatment of women with early breast cancer. Health Technology Assessment, 20 (10), pp. 1-202
- Thamm, Douglas, Dorling, Leila, Kar, Siddhartha, Michailidou, Kyriaki, Hiller, Louise, Vallier, Anne-Laure, Ingle, Susan, Hardy, Richard, Bowden, Sarah J., Dunn, Janet A., Twelves, Chris, Poole, Christopher J., Caldas, Carlos, Earl, Helena M., Pharoah, Paul D. P., Abraham, Jean E., 2016. The relationship between common genetic markers of breast cancer risk and chemotherapy-induced toxicity : a case-control study. PLoS One, 11 (7)
- Scott, R. A., Freitag, D. F., Li, L., Chu, A. Y., Surendran, P., Young, R., Grarup, N., Stancakova, A., Chen, Y., Varga, T. V., Yaghootkar, H., Luan, J., Zhao, J. H., Willems, S. M., Wessel, J., Wang, S., Maruthur, N., Michailidou, K., Pirie, A., van der Lee, S. J. et al (Select to open full list), 2016. A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. Science Translational Medicine, 8 (341)
- Mehanna, Hisham, Wong, Wai-Lup, McConkey, Christopher C., Rahman, Joy K., Robinson, Max, Hartley, Andrew G.J., Nutting, Christopher, Powell, Ned, Al-Booz, Hoda, Robinson, Martin, Junor, Elizabeth, Rizwaah, Mohammed, von Zeidler, Sandra L. V., Wieshmann, Hulya, Hulme, Claire, Smith, Alison F., Hall, Peter, Dunn, Janet A., 2016. PET-CT surveillance versus neck dissection in advanced head and neck cancer. New England Journal Of Medicine, 374 (15), pp. 1444-1454
- Hartley, A., Fong, C., Sanghera, P., Wong, W. L., McConkey, Christopher C., Rahman, J., Nutting, C. M., Al-Booz, H., Robinson, M., Junor, E., Rizwaah, M., Dunn, Janet A., Mehanna, H., 2016. Radiation therapy variation in the Randomized Phase 3 Positron Emission Tomography Neck Study. International Journal of Radiation Oncology Biology Physics, 96 (2)
- Taylor-Phillips, Sian, Wallis, Matthew G., Jenkinson, David J., Adekanmbi, Victor, Parsons, Helen, Dunn, Janet A., Stallard, Nigel, Szczepura, Ala, Gates, Simon, Kearins, Olive, Duncan, Alison, Hudson, Sue, Clarke, Aileen, 2016. Effect of using the same vs different order for second readings of screening mammograms on rates of breast cancer detection : a randomized clinical trial. JAMA: The Journal of the American Medical Association, 315 (18), pp. 1956-1965
- Huish, S. A., Fletcher, S., Dunn, Janet A., Hewison, M., Bland, R., 2015. Prevalence and treatment of hypovitaminosis D in the haemodialysis population of Coventry. Journal of Steroid Biochemistry and Molecular Biology, 164, pp. 214-217
- Balmer, Claire E., Griffiths, Frances, Dunn, Janet A., 2015. A 'new normal' : exploring the disruption of a poor prognostic cancer diagnosis using interviews and participant-produced photographs. Health, 19 (5), pp. 451-472
- Abraham, Jean E., Hiller, Louise, Dorling, Leila, Vallier, Anne-Laure, Dunn, Janet A., Bowden, Sarah, Ingle, Susan, Jones, Linda, Hardy, Richard, Twelves, Christopher, Poole, Christopher J., Pharoah, Paul D. P., Caldas, Carlos, Earl, Helena M., 2015. A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities. BMC Medicine, 13 (1)
- Guo, Q., Schmidt, M. K., Kraft, P., Canisius, S., Chen, C., Khan, S., Tyrer, J., Bolla, M. K., Wang, Q., Dennis, J., Michailidou, K., Lush, M., Kar, S., Beesley, J., Dunning, A. M., Shah, M., Czene, K., Darabi, H., Eriksson, M., Lambrechts, D. et al (Select to open full list), 2015. Identification of Novel Genetic Markers of Breast Cancer Survival. JNCI Journal of the National Cancer Institute, 107 (5)
- Treweek, Shaun, Altman, Douglas G., Bower, Peter, Campbell, Marion, Chalmers, Iain, Cotton, Seonaidh, Craig, Peter S., Crosby, David, Davidson, Peter, Devane, Declan, Duley, Lelia, Dunn, Janet A., Elbourne, Diana, Farrell, Barbara, Gamble, Carrol, Gillies, Katie, Hood, Kerry, Lang, Trudie, Littleford, Roberta, Loudon, Kirsty et al (Select to open full list), 2015. Making randomised trials more efficient : report of the first meeting to discuss the Trial Forge platform. Trials, 16 (1), pp. 1-9
- Balmer, Claire E., Griffiths, Frances, Dunn, Janet A., 2015. A review of the issues and challenges involved in using participant-produced photographs in nursing research. Journal of Advanced Nursing, 71 (7), pp. 1726-1737
- Balmer, Claire E., Griffiths, Frances, Dunn, Janet A., 2015. A review of the issues and challenges involved in using participant-produced photographs in nursing research. Journal of Advanced Nursing, 71 (7), pp. 1726-1737
- Earl, Helena M., Hiller, Louise, Dunn, Janet A., Blenkinsop, Clare, Grybowicz, Louise, Vallier, Anne-Laure, Abraham, Jean, Thomas, Jeremy, Provenzano, Elena, Hughes-Davies, Luke, Gounaris, Ioannis, McAdam, Karen, Chan, Stephen, Ahmad, Rizvana, Hickish, Tamas, Houston, Stephen, Rea, Daniel, Bartlett, John, Caldas, Carlos, Cameron, David A et al (Select to open full list), 2015. Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis) : an open-label, randomised, phase 3 trial. The Lancet Oncology, 16 (6), pp. 656-666
- Bartlett, J. M. S., McConkey, Christopher C., Munro, A. F., Desmedt, C., Dunn, Janet A., Larsimont, D., O'Malley, F. P., Cameron, D. A., Earl, H., Poole, Christopher J., Shepherd, L. E., Cardoso, F., Jensen, M., Caldas, C., Twelves, C. J., Rea, D. W., Ejlertsen, B., Di Leo, A., Pritchard, K. I., 2015. Predicting anthracycline benefit : TOP2A and CEP17-not only but also. European Journal of Cancer Care, 33 (15), pp. 1680-1687
- Ali, H. R., Glont, S.- E., Blows, F. M., Provenzano, E., Dawson, S.- J., Liu, B., Hiller, Louise, Dunn, Janet A., Poole, C. J., Bowden, S., Earl, H. M., Pharoah, P. D. P., Caldas, C., 2015. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Annals of Oncology, 26 (7)
- Earl, Helena, Provenzano, Elena, Abraham, Jean, Dunn, Janet A., Vallier, Anne-Laure, Gounaris, Ioannis, Hiller, Louise, 2015. Neoadjuvant trials in early breast cancer : pathological response at surgery and correlation to longer term outcomes ? what does it all mean?. BMC Medicine, 13 (1)
- Bryan, R. T., Evans, T., Dunn, Janet A., Iqbal, Gulnaz, Bathers, S., Collins, S. I., James, Nicholas D., Catto, J. W. F., Wallace, D. M. A., 2015. A comparative analysis of the influence of gender, pathway delays, and risk factor exposures on the long-term outcomes of bladder cancer. European Urology Focus, 1 (1), pp. 82-89
- Pirie, Ailith, Guo, Qi, Kraft, Peter, Canisius, Sander, Eccles, Diana M, Rahman, Nazneen, Nevanlinna, Heli, Chen, Constance, Khan, Sofia, Tyrer, Jonathan, Bolla, Manjeet K, Wang, Qin, Dennis, Joe, Michailidou, Kyriaki, Lush, Michael, Dunning, Alison M, Shah, Mitul, Czene, Kamila, Darabi, Hatef, Eriksson, Mikael et al (Select to open full list), 2015. Common germline polymorphisms associated with breast cancer-specific survival. Breast Cancer Research, 17 (1)
- Nelson, Laura, McKenn, Hayley D., Marshall, A. (Andrea)?, Mulrane, Laoighse, Starczynski, Jane, Storr, Sarah J., Lanigan, Fiona, Byrne, Christopher, Arthur, Ken, Hegarty, Shauna, Ali, Ahlam Abdunnabi, Furlong, Fiona, McCarthy, Helen, Ellis, Ian O., Green, Andrew R., Rakha, Emad, Young, Leonie, Kunkler, Ian, Thomas, Jeremy, Jack, Wilma et al (Select to open full list), 2015. FKBPL : a marker of good prognosis in breast cancer. Oncotarget, 6 (14), pp. 12209-12223
- Ford, Hugo, Marshall, A. (Andrea), Bridgewater, John A., Janowitz, Tobias, Coxon, Fareeda Y., Wadsley, Jonathan, Mansoor, Wasat, Fyfe, David, Madhusudan, Srinivasan, Middleton, Gary W., Swinson, Daniel, Falk, Stephen, Chau, Ian, Cunningham, David, Kareclas, Paula, Cook, Natalie, Blazeby, Jane M., Dunn, Janet A., 2014. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02) : an open-label, phase 3 randomised controlled trial. The Lancet Oncology, 15 (1), pp. 78-86
- Earl, Helena M., Vallier, Anne-Laure, Hiller, Louise, Fenwick, Nicola, Young, Jennie, Iddawela, Mahesh, Abraham, Jean, Hughes-Davies, Luke, Gounaris, Ioannis, McAdam, Karen, Houston, Stephen, Hickish, Tamas, Skene, Anthony, Chan, Stephen, Dean, Susan, Ritchie, Diana, Laing, Robert, Harries, Mark, Gallagher, Christopher, Wishart, Gordon et al (Select to open full list), 2014. Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial. The Lancet Oncology, Volulme 15 (2), pp. 201-212
- Molyneux, Elizabeth, Merrick, Blair, Khanim, Farhat L., Banda, Kondwani, Dunn, Janet A., Iqbal, Gulnaz, Bunce, Christopher M., Drayson, Mark T., 2014. Bezafibrate and medroxyprogesterone acetate in resistant and relapsed endemic Burkitt lymphoma in Malawi ; an open-label, single-arm, phase 2 study (ISRCTN34303497). British Journal of Haematology, 164 (6), pp. 888-890
- Abraham, J. E., Guo, Q., Dorling, L., Tyrer, J., Ingle, S., Hardy, R., Vallier, A.-L., Hiller, Louise, Burns, R., Jones, L., Bowden, S. J., Dunn, Janet A., Poole, C. J., Caldas, C., Pharoah, P. P. D., Earl, Helena M., 2014. Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with paclitaxel. Clinical Cancer Research, 20 (9), pp. 2466-2475
- Corrie, Pippa G., Marshall, A. (Andrea)?, Dunn, Janet A., Middleton, Mark R., Nathan, Paul D., Gore, Martin, Davidson, Neville, Nicholson, Steve, Kelly, Charles G., Marples, Maria, Danson, Sarah J., Marshall, Ernest, Houston, Stephen J., Board, Ruth E., Waterston, Ashita M., Nobes, Jenny P., Harries, Mark, Kumar, Satish, Young, Gemma, Lorigan, Paul, 2014. Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M) : preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. The Lancet Oncology, 15 (6), pp. 620-630
- Earl, Helena M., Vallier, Anne-Laure, Hiller, Louise, Fenwick, Nicola, Young, Jennie, Iddawela, Mahesh, Abraham, Jean, Hughes-Davies, Luke, Gounaris, Ioannis, McAdam, Karen, Houston, Stephen, Hickish, Tamas, Skene, Anthony, Chan, Stephen, Dean, Susan, Ritchie, Diana, Laing, Robert, Harries, Mark, Gallagher, Christopher, Wishart, Gordon et al (Select to open full list), 2014. Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo) : an open-label, 2×2 factorial randomised phase 3 trial. The Lancet Oncology, 15 (2), pp. 201-212
- Balmer, Claire E., Griffiths, Frances, Dunn, Janet A., 2014. A qualitative systematic review exploring lay understanding of cancer by adults without a cancer diagnosis. Journal of Advanced Nursing, 70 (8), pp. 1688-1701
- Ali, H. R., Provenzano, E., Dawson, S.- J., Blows, F. M., Liu, B., Shah, M., Earl, H. M., Poole, C. J., Hiller, Louise, Dunn, Janet A., Bowden, S. J., Twelves, C., Bartlett, J. M. S., Mahmoud, S. M. A., Rakha, E., Ellis, I. O., Liu, S., Gao, D., Nielsen, T. O., Pharoah, P. D. P. et al (Select to open full list), 2014. Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients. Annals of Oncology, 25 (8), pp. 1536-1543
- Wason, J., Marshall, A. (Andrea)?, Dunn, Janet A., Stein, R. C., Stallard, Nigel, 2014. Adaptive designs for clinical trials assessing biomarker-guided treatment strategies. British Journal of Cancer, 110 (8), pp. 1950-1957
- Ali, H. R., Provenzano, E., Dawson, S.- J., Blows, F. M., Liu, B., Shah, M., Earl, H. M., Poole, C. J., Hiller, Louise, Dunn, Janet A., Bowden, S. J., Twelves, C., Bartlett, J. M. S., Mahmoud, S. M. A., Rakha, E., Ellis, I. O., Liu, S., Gao, D., Nielsen, T. O., Pharoah, P. D. P. et al (Select to open full list), 2014. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Annals of Oncology, 25 (8), pp. 1536-1543
- Dunn, Janet A., Donnelly, P. K., Marshall, A. (Andrea)?, Wilcox, M., Watson, E., Young, Annie M., Balmer, Claire E., Ramirez, M., Hartup, S., Maxwell, A.J., Evans, A. J., 2014. Follow-up in early breast cancer ? a surgical and radiological perceptive. Clinical Oncology, 26 (10), pp. 625-629
- Taylor-Phillips, Sian, Wallis, Matthew G., Parsons, Helen, Dunn, Janet A., Stallard, Nigel, Campbell, Helen, Sellars, Sarah, Szczepura, Ala, Gates, Simon, Clarke, Aileen, 2014. Changing case order to optimise patterns of performance in mammography screening (CO-OPS) : study protocol for a randomized controlled trial. Trials, 15
- Bryan, Richard T., Zeegers, Maurice P., van Roekel, Eline H., Bird, Deborah, Grant, Margaret R., Dunn, Janet A., Bathers, Sarah, Iqbal, Gulnaz, Khan, Humera S., Collins, Stuart I., Howman, Andrew, Deshmukh, Nayneeta S., James, Nicholas D., Cheng, Kar Keung, Wallace, D. Michael A., 2013. A comparison of patient and tumour characteristics in two UK bladder cancer cohorts separated by 20 years. BJU International, 112 (2), pp. 169-175
- Bartlett, J., Canney, P., Campbell, A. M., Cameron, D., Donovan, Jenny, Dunn, Janet A., Earl, Helena M., Francis, A., Hall, P., Harmer, V., Higgins, Helen B., Hillier, L., Hulme, C., Hughes-Davies, Luke, Makris, A., Morgan, A., McCabe, Chris, Pinder, S., Poole, Christopher J., Rea, D. et al (Select to open full list), 2013. Selecting breast cancer patients for chemotherapy : the opening of the UK OPTIMA trial. Clinical Oncology, 25 (2), pp. 109-116
- Bradley, A., Marshall, A., Stonehewer, L., Reaper, L., Parker, K., Bevan-Smith, E., Jordan, C., Gillies, J., Agostini, P., Bishay, E., Kalkat, M., Steyn, R., Rajesh, P., Dunn, Janet A., Naidu, B., 2013. Pulmonary rehabilitation programme for patients undergoing curative lung cancer surgery. European Journal of Cardio-thoracic Surgery, 44 (4), pp. e266-e271
- Ali, Alaa M., Provenzano, E., Barlett, J. M., Abraham, J., Driver, Kristy, Twelves, Chris, Munro, Alison F., Poole, Christopher, Hiller, Louise, Dunn, Janet A., Earl, Helena M., Caldas, Carlos, Pharoah, Paul, 2013. Prognosis of early breast cancer by immunohistochemistry defined intrinsic subtypes in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial. International Journal of Cancer, 133 (6), pp. 1470-1478
- Ali, Alaa M., Provenzano, Elena, Bartlett, John M. S., Abraham, Jean, Driver, Kristy, Munro, Alison F., Twelves, Chris, Poole, Christopher J., Hiller, Louise, Dunn, Janet A., Earl, Helena M., Caldas, Carlos, Pharoah, Paul D., 2013. Prognosis of early breast cancer by immunohistochemistry defined intrinsic sub-types in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial. International Journal of Cancer, 133 (6), pp. 1470-1478
- Provenzano, E., Vallier, A. -L., Champ, R., Walland, K., Bowden, S. (Sarah), Grier, Anna, Fenwick, Nicola, Abraham, J. (Janet), Iddawela, M., Caldas, C., Hiller, Louise, Dunn, Janet A., Earl, Helena M., 2013. A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial. British Journal of Cancer, 108 (4), pp. 866-872
- McCaul, James A., Cymerman, James A., Hislop, Stuart, McConkey, Christopher C., McMahon, Jeremy, Mehanna, Hisham M., Shaw, Richard, Sutton, David N., Dunn, Janet A., 2013. LIHNCS - Lugol's iodine in head and neck cancer surgery : a multicentre, randomised controlled trial assessing the effectiveness of Lugol's iodine to assist excision of moderate dysplasia, severe dysplasia and carcinoma in situ at mucosal resection margins of oral and oropharyngeal squamous cell carcinoma : study protocol for a randomised controlled trial. Trials, 14 (1)
- Spooner, David A., Stocken, D. D., Jordan, S., Bathers, S., Dunn, Janet A., Jevons, C., Dodson, L., Morrison, J. M., Oates, G. D., Grieve, R. J., 2012. A randomised controlled trial to evaluate both the role and the optimal fractionation of radiotherapy in the conservative management of early breast cancer. Clinical Oncology, Vol.24 (No.10), pp. 697-706
- Iqbal, Gulnaz, Johnson, Mark R. D., Szczepura, Ala, Wilson, Sue, Gumber, Anil, Dunn, Janet A., 2012. UK ethnicity data collection for healthcare statistics : the South Asian perspective. BMC Public Health, Vol.12 (No.1)
- Bradley, A., Marshall, A. (Andrea), Abdelaziz, M., Hussain, K., Agostini, P., Bishay, E., Kalkat, M., Steyn, R., Rajesh, P., Dunn, Janet A., Naidu, Babu V., 2012. Thoracoscore fails to predict complications following elective lung resection. European Respiratory Journal, Vol.40 (No.6), pp. 1496-1501
- Balmer, Claire E., Griffiths, Frances, Dunn, Janet A., 2012. Using photovoice to study the experience of living with and beyond the diagnosis of a poor prognostic cancer. BMJ Supportive & Palliative Care, 2 (Suppl_1), pp. A28-A28
- Iqbal, Gulnaz, Johnson, Mark R. D., Szczepura, Ala, Gumber, Anil, Wilson, Sue, Dunn, Janet A., 2012. Ethnicity data collection in the UK: The healthcare professional's perspective. Diversity and equality in health and care, 9 (4), pp. 281-290
- Nankivell, Paul, Dunn, Janet A., Langman, Michael J., Mehanna, Hisham M., 2012. Feasibility of recruitment to an oral dysplasia trial in the United Kingdom. Head & Neck Oncology, 4 (1)
- Taggart, Frances M., Donnelly, Peter K., Dunn, Janet A., 2012. Options for early breast cancer follow-up in primary and secondary care : a systematic review. BMC Cancer, Vol.12 (No.1)
- Earl, Helena M., Hiller, Louise, Dunn, Janet A., Vallier, A. -L., Bowden, S. J., Jordan, S. D., Blows, F., Munro, A., Bathers, S., Grieve, R., Spooner, David A., Agrawal, R., Fernando, I., Brunt, A. M., O'Reilly, S. M., Crawford, S. Michael, Rea, D. W., Simmonds, P., Mansi, J. L., Stanley, A. et al (Select to open full list), 2012. Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer : results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials. British Journal of Cancer, Vol.107 (No.8), pp. 1257-1267
- Tudur Smith, Catrin, Stocken, Deborah D., Dunn, Janet A., Cox, Trevor F., Ghaneh, Paula, Cunningham, David, Neoptolemos, John P., 2012. The value of source data verification in a cancer clinical trial. PLoS ONE, Vol.7 (No.12)
- Campbell, H. E., Epstein, D., Bloomfield, D., Griffin, S., Manca, A., Yarnold, J., Bliss, J., Johnson, L., Earl, Helena M., Poole, Christopher J., Hiller, Louise, Dunn, Janet A., Hopwood, P., Barrett-Lee, P., Ellis, P., Cameron, D., Harris, A. L., Gray, A. M., Sculpher, Mark J., 2011. The cost-effectiveness of adjuvant chemotherapy for early breast cancer : a comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses. European Journal of Cancer, Vol.47 (No.17), pp. 2517-2530
- Ishak, K. Jack, Caro, J. Jaime, Drayson, Mark T., Dimopoulos, Meletios, Weber, Donna, Augustson, Bradley, Child, J. Anthony, Knight, Robert, Iqbal, Gulnaz, Dunn, Janet A., Shearer, Arran, Morgan, Gareth, 2011. Adjusting for patient crossover in clinical trials using external data : a case study of lenalidomide for advanced multiple myeloma. Value in Health, Vol.14 (No.5), pp. 672-678
- Hiller, Louise, Dunn, Janet A., Higgins, Helen B., Ogburn-Storey, Emma, Loi, Shrushma, Vallier, Anne-Laure, Earl, Helena M., 2011. Optimising patient recall of adverse events over prolonged time periods. Trials, Vol.12 (Suppl.1)
- Midgley, Rachel S., McConkey, Christopher C., Johnstone, Elaine C., Dunn, Janet A., Smith, Justine L., Grumett, Simon A., Julier, Patrick, Iveson, Claire, Yanagisawa, Yoko, Warren, Bryan, Langman, Michael J., Kerr, David J., 2010. Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial. Journal of Clinical Oncology, Vol.28 (No.30), pp. 4575-4580
- Davidson, N., Gelber, R., Piccart, M., Pruneri, G., Pritchard, K., Ravdin, P., Robertson, J., Swain, S., Abe, O., Abe, R., Enomoto, K., Kikuchi, K., Koyama, H., Masuda, H., Nomura, Y., Ohashi, Y., Sakai, K., Sugimachi, K., Toi, M., Tominaga, T. et al (Select to open full list), 2010. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. Journal of the National Cancer Institute - Monographs, 41, pp. 162-177
- Bartlett, John M. S., Munro, Alison F., Dunn, Janet A., McConkey, Christopher C., Jordan, S., Twelves, Chris, Cameron, D., Thomas, Jeremy St. J., Campbell, Fiona M., Rea, Daniel W., Provenzano, Elena, Caldas, Carlos, Pharaoh, Paul, Hiller, Louise, Earl, Helena M., Poole, Christopher, 2010. Predictive markers of anthracycline benefit : a prospectively planned analysis of the UK national epirubicin adjuvant trial (NEAT/BR9601). Lancet Oncology, Vol.11 (No.3), pp. 266-274
- Cunningham, David, Chau, I., Stocken, Deborah D., Valle, J. W., Smith, D., Steward, William, Harper, Peter G., Dunn, Janet A., Tudur-Smith, C., West, J., Falk, S., Crellin, A., Adab, F., Thompson, J., Leonard, P., Ostrowski, J., Eatock, M., Scheithauer, W., Herrmann, R., Neoptolemos, John, 2009. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. Journal of Clinical Oncology, Vol.27 (No.33), pp. 5513-5518
- Iqbal, Gulnaz, Gumber, Anil, Johnson, Mark R. D., Szczepura, Ala, Wilson, Sue, Dunn, Janet A., 2009. Improving ethnicity data collection for health statistics in the UK. Diversity in Health and Care, Vol.6 (No.4), pp. 267-285
- Earl, Helena M., Hiller, Louise, Dunn, Janet A., Bathers, S., Harvey, P., Stanley, A., Grieve, R. J., Agrawal, R. K., Fernando, I. N., Brunt, A. M., McAdam, K., O'Reilly, S., Rea, D. W., Spooner, David A., Poole, Christopher, 2008. NEAT : national epirubicin adjuvant trial - toxicity, delivered dose intensity and quality of life. British Journal of Cancer, Vol.99 (No.8), pp. 1226-1231
- Biswas, S., Wrigley, J., East, C., Hern, A., Marshall, A. (Andrea), Dunn, Janet A., Lorigan, P., Middleton, M. (Mark), Corrie, P., 2008. A randomised trial evaluating Bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma : an update. ecancermedicalscience, Vol.2
- Wardley, A. M., Hiller, Louise, Howard, H. C., Dunn, Janet A., Bowman, A., Coleman, R. E., Fernando, I. N., Ritchie, D. M., Earl, Helena M., Poole, Christopher J., 2008. tAnGo : a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer : a prospective pulmonary, cardiac and hepatic function evaluation. British Journal of Cancer, Vol.99 (No.4), pp. 597-603
- Kerr, David J., Dunn, Janet A., Langman, Michael J., Smith, Justine L., Midgley, Rachel S. J., Stanley, Andrew, Stokes, Joanne C., Julier, Patrick, Iveson, Claire, Duvvuri, Ravi, McConkey, Christopher C., 2007. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. New England Journal Of Medicine, Vol.357 (No.4), pp. 360-369
- Kerr, David J., Dunn, Janet A., Langman, Michael J., Smith, Justine L., Midgley, Rachel S. J., Stanley, Andrew, Stokes, Joanne C., Julier, Patrick, Iveson, Claire, Duvvuri, Ravi, McConkey, Christopher C., 2007. Rofecoxib and cardiovascular adverse eventsin adjuvant treatment of colorectal cancer. New England Journal Of Medicine, Vol.357 (No.4), pp. 360-369
- Wilson, Sue, Dr, Wakelam, Michael J.O., Hobbs, Richard F. D., Ryan, Angela V., Dunn, Janet A., Redman, Val. D., Patrick, Fiona, Colbourne, Lynne, Martin, Ashley, 2006. Evaluation of the accuracy of serum MMP-9 as a test for colorectal cancer in a primary care population. BMC Cancer, Vol.6 (No.25)
- Poole, Christopher J., Earl, Helena M., Hiller, Louise, Dunn, Janet A., Bathers, Sarah, Grieve, Robert J., Spooner, David A., Agrawal, Rajiv K., Brunt, A. Murray, O'Reilly, Susan M., Crawford, S. Michael, Rea, Daniel W., Simmonds, Peter, Mansi, Janine L., Stanley, Andrew, Harvey, Peter, McAdam, Karen, Foster, Liz, Leonard, Robert C. F., Twelves, Chris, 2006. Epirubicin and cyclophosphamide, methotrexate,and fluorouracil as adjuvant therapy for early breast cancer. New England Journal of Medicine, Vol.355 (No.18), pp. 1851-1862
- Ryan, Angela V., Wilson, Sue, Dr, Wakelam, Michael J. O., Warmington, Sally A., Dunn, Janet A., Hodgkin, Richard F. D., Martin, Ashley, Ismail, Tariq, 2006. A prospective study to assess the value of MMP-9 in improving the appropriateness of urgent referrals for colorectal cancer. BMC Cancer, Vol.6 (No.251)
- Drayson, M., Begum, G., Basu, S., Makkuni, S., Dunn, Janet A., Barth, N., Child, J. A., 2006. Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma : an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials. Blood, 108 (6), pp. 2013-2019
- Augustson, B. M., Begum, G., Dunn, Janet A., Barth, N. J., Davies, F., Morgan, G., Behrens, J., Smith, A., Child, J. A., Drayson, M. T., 2005. Early mortality after diagnosis of multiple myeloma: Analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 - Medical Research Council Adult Leukaemia Working Party. Journal of Clinical Oncology, 23 (36), pp. 9219-9226
- Lovell, R., Dunn, Janet A., Begum, G., Barth, N. J., Plant, T., Moss, P. A., Drayson, M. T., Pratt, G., 2005. Soluble syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival. British Journal of Haematology, 130 (4), pp. 542-548
- Bassi, C., Stocken, D. D., Olah, A., Friess, H., Buckels, J., Hickey, H., Dervenis, C., Dunn, Janet A., Deakin, M., Carter, R., Ghaneh, P., Neoptolemos, J. P., Büchler, M. W., 2005. Influence of surgical resection and post-operative complications on survival following adjuvant treatment for pancreatic cancer in the ESPAC-1 randomized controlled trial. Digestive Surgery, 22 (5), pp. 353-363
- Neoptolemos, J. P., Stocken, D. D., Friess, H., Bassi, C., Dunn, Janet A., Hickey, H., Beger, H., Fernandez-Cruz, L., Dervenis, C., Lacaine, F., Falconi, M., Pederzoli, P., Pap, A., Spooner, D., Kerr, D. J., Büchler, M. W., 2004. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. New England Journal Of Medicine, 350 (12), pp. 1200-1210
- McCloskey, E. V., Dunn, Janet A., Kanis, J. A., MacLennan, I. C. M., Drayson, M. T., 2002. Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. British Journal of Haematology, 113 (4), pp. 1035-1043
- Wallace, D. M. A., Bryan, R. T., Dunn, Janet A., Begum, G., Bathers, S., 2002. Delay and survival in bladder cancer. BJU International, 89 (9), pp. 868-878
- Young, Annie M., Marsden, J., Goodman, A., Burton, Andrea, Dunn, Janet A., 2001. Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-a) in metastatic melanoma. Clinical Oncology, 13 (6), pp. 458-465
- Neoptolemos, J. P., Dunn, Janet A., Stocken, D. D., Almond, J., Link, K., Beger, H., Bassi, C., Falconi, M., Pederzoli, P., Dervenis, C., Fernandez-Cruz, L., Lacaine, F., Pap, A., Spooner, D., Kerr, D. J., Friess, H., Büchler, M. W., 2001. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer : a randomised controlled trial. Lancet, 358 (9293), pp. 1576-1585
- Cooke, P. W., Dunn, Janet A., Latief, T., Bathers, S., James, N. D., Wallace, D. M. A., 2000. Long-term risk of salvage cystectomy after radiotherapy for muscle- invasive bladder cancer. European Urology, 38 (3), pp. 279-286
- Herod, J., Burton, A., Buxton, J., Tobias, J., Luesley, D., Jordan, S., Dunn, Janet A., Poole, C. J., 2000. A randomised, prospective, phase III clinical trial of primary bleomycin, ifosfamide and cisplatin (BIP) chemotherapy followed by radiotherapy versus radiotherapy alone in inoperable cancer of the cervix. Annals of Oncology, 11 (9), pp. 1175-1181
- Langman, M. J. S., Dunn, Janet A., Whiting, J. L., Burton, A., Hallissey, M. T., Fielding, J. W. L., Kerr, D. J., 1999. Prospective, double-blind, placebo-controlled randomized trial of cimetidine in gastric cancer. British Journal of Cancer, 81 (8), pp. 1356-1362
- McCloskey, E. V., Maclennan, I. C. M., Drayson, M. T., Chapman, C., Dunn, Janet A., Kanis, J. A., 1998. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. British Journal of Haematology, 100 (2), pp. 317-325
- Whiting, J. L., Hallissey, M. T., Fielding, J. W. L., Dunn, Janet A., 1998. Screening for gastric cancer by Helicobacter pylori serology : a retrospective study. British Journal of Surgery, 85 (3), pp. 408-411
- Drayson, M. T., Chapman, C. E., Dunn, Janet A., Olujohungbe, A. B., Maclennan, I. C. M., 1998. MRC trial of a2b-interferon maintenance therapy in first plateau phase of multiple myeloma. British Journal of Haematology, 101 (1), pp. 195-202
- Phillips, L., Lindley, D. V., Longford, N. T., Newby, M. J., Smith, T. M. F., Barnard, G. A., Cox, D. R., Leonard, T., Abdullah, S., Garthwaite, P., Abrams, K. R., Dunn, Janet A., Black, P. K., Blyth, S., Brown, P. J., Dickey, J. M., Flournoy, N., Smith, J. Q., 1998. Discussion on the papers on 'Elicitation'. Journal Of The Royal Statistical Society Series D -The Statistician, 47 (1), pp. 55-68
- Bailey, N. P., Stuart, N. S. A., Bessell, E. M., Child, J. A., Norfolk, D., Fletcher, J., Grieve, R. J., Simmons, A. V., Barnard, D. L., Jack, A., Farish, J., Dunn, Janet A., Woodroffe, C. M., Stack, C., Cullen, M. H., 1998. Five-year follow-up of a prospective randomised multi-centre trial of weekly chemotherapy (CAPOMET) versus cyclical chemotherapy (CHOP-Mtx) in the treatment of aggressive non-Hodgkin's lymphoma. Annals of Oncology, 9 (6), pp. 633-638
- Etherington, L. J., Luesley, D. M., Shafi, M. I., Dunn, Janet A., Jordan, J. A., 1998. Cytological prediction of cervical intraepithelial neoplasia grade 3 : does size of the lesion matter?. Journal of Lower Genital Tract Disease, 2 (1), pp. 17-18
- Etherington, I. J., Luesley, D. M., Shafi, M. I., Dunn, Janet A., Hiller, Louise, Jordan, J. A., 1997. Observer variability among colposcopists from the West Midlands region. BJOG: An International Journal of Obstetrics and Gynaecology, 104 (12), pp. 1380-1384
- Shafi, M. I., Luesley, D. M., Jordan, J. A., Dunn, Janet A., Rollason, T. P., Yates, M., 1997. Randomised trial of immediate versus deferred treatment strategies for the management of minor cervical cytological abnormalities. BJOG: An International Journal of Obstetrics and Gynaecology, 104 (5), pp. 590-594
- Etherington, I. J., Dunn, Janet A., Shafi, M. I., Smith, T., Luesley, D. M., 1997. Video colpography : a new technique for secondary cervical screening. BJOG: An International Journal of Obstetrics and Gynaecology, 104 (2), pp. 150-153
- Van Geene, P., Varma, R., Dunn, Janet A., Chan, K. K., Luesley, D. M., 1996. The prognostic significance of intraperitoneal growth characteristics in epithelial ovarian carcinoma. International Journal of Gynecological Cancer, 6 (3), pp. 219-224
- Priestman, T. J., Dunn, Janet A., Brada, M., Rampling, R., Baker, P. G., 1996. Final results of the Royal College of Radiologists' Trial comparing two different radiotherapy schedules in the treatment of cerebral metastases. Clinical Oncology, 8 (5), pp. 308-315
- Bramhall, S. R., Stamp, G. W. H., Dunn, Janet A., Lemoine, N. R., Neoptolemos, J. P., 1996. Expression of collagenase (MMP2), stromelysin (MMP3) and tissue inhibitor of the metalloproteinases (TIMP1) in pancreatic and ampullary disease. British Journal of Cancer, 73 (8), pp. 972-978
- Clinton, O. P., Priestman, T. J., Latief, T. N., Earl, H., Murphy, A., Blackledge, G. R. P., Dunn, Janet A., Baker, P., 1995. A prospective randomized trial to evaluate different oral dose regimens of medroxyprogesterone acetate in women with advanced breast cancer. Clinical Oncology, 7 (4), pp. 251-256
- Yu, C. C. W., Levison, D. A., Dunn, Janet A., Ward, L. C., Demonakou, M., Allum, W. H., Hallisey, M. T., 1995. Pathological prognostic factors in the second British Stomach Cancer Group trial of adjuvant therapy in resectable gastric cancer. British Journal of Cancer, 71 (5), pp. 1106-1110
- Liu, B., Earl, H. M., Poole, C. J., Dunn, Janet A., Kerr, D. J., 1995. Etoposide protein binding in cancer patients. Cancer Chemotherapy and Pharmacology, 36 (6), pp. 506-512
- Shafi, M. I., Dunn, Janet A., Chenoy, R., Buxton, E. J., Williams, C., Luesley, D. M., 1994. Digital imaging colposcopy, image analysis and quantification of the colposcopic image. BJOG: An International Journal of Obstetrics & Gynaecology, 101 (3), pp. 234-238
- Lynch, T. H., Waymont, B., Dunn, Janet A., Hughes, M. A., Wallace, D. M. A., 1994. Rapid diagnostic service for patients with haematuria. British Journal of Urology, 73 (2), pp. 147-151
- Luesley, D., Blomfield, P., Dunn, Janet A., Shafi, M., Chenoy, R., Buxton, J., 1994. Cigarette smoking and histological outcome in wom with mildly dyskaryotic cervical smears. BJOG: An International Journal of Obstetrics & Gynaecology, 101 (1), pp. 49-52
- Stonelake, P. S., Bundred, N. J., Neoptolemos, N. P., Baker, P. R., Baker, P. G., Gillespie, W. M., Dunn, Janet A., Spooner, D., Morrison, J. M., Oates, G. D., Lee, M. J. R., Neoptolemos, J. P., Chan, S. Y., 1994. Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer. European Journal of Cancer Care, 30 (1), pp. 5-11
- Lynch, T. H., Waymont, B., Dunn, Janet A., Hughes, M. A., Wallace, D. M. A., 1994. Repeat testing for haematuria and underlying urological pathology. British Journal of Urology, 74 (6), pp. 730-732
- Hutchinson, R., Tyrrell, P. N. M., Kumar, D., Dunn, Janet A., Li, J. K. W., Allan, R. N., 1994. Pathogenesis of gall stones in Crohn's disease : an alternative explanation. Gut, 35 (1), pp. 94-97
- Maclennan, I. C. M., Drayson, M., Dunn, Janet A., 1994. Current issues in cancer : multiple myeloma. BMJ Open, 308 (6935), pp. 1033-1036
- Hallissey, M. T., Dunn, Janet A., Ward, L. C., Allum, W. H., 1994. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer : five-year follow-up. The Lancet, 343 (8909), pp. 1309-1312
- Silverman, D. T., Dunn, Janet A., Hoover, R. N., Schiffiman, M., Lillemoe, K. D., Schoenberg, J. B., Brown, L. M., Greenberg, R. S., Hayes, R. B., Swanson, G. M., Wacholder, S., Schwartz, A. G., Liff, J. M., Pottern, L. M., 1994. Cigarette smoking and pancreas cancer : a case-control study based on direct interviews. Journal of the National Cancer Institute, 86 (20), pp. 1510-1516
- Hallissey, M. T., Dunn, Janet A., Fielding, J. W. L., 1994. Evaluation of pepsinogen a and gastrin-17 as markers of gastric cancer and high-risk pathologic conditions. Scandinavian Journal of Gastroenterology, 29 (12), pp. 1129-1134
- Hallissey, M. T., Jewkes, A. J., Dunn, Janet A., Ward, L., Fielding, J. W. L., 1993. Resection-line involvement in gastric cancer : a continuing problem. British Journal of Surgery, 80 (11), pp. 1418-1420
- Stonelake, P. S., Powell, J., Dunn, Janet A., Warwick, Jane, Bramhall, S. R., Neoptolemos, J. P., Baker, P. R., Morrison, J. M., 1993. Influence of timing of surgery during menstrual, cycle on survival of premenopausal women with operable breast cancer. The Breast, 2 (3), pp. 201-202
- Shafi, M. I., Dunn, Janet A., Finn, C. B., Kehoe, S., Buxton, E. J., Jordan, J. A., Luesley, D. M., 1993. Characterization of high- and low-grade cervical intraepithelial neoplasia. International Journal of Gynecological Cancer, 3 (4), pp. 203-207
- Wallace, L. M., Priestman, S. G., Dunn, Janet A., Priestman, T. J., 1993. The quality of life of early breast cancer patients treated by two different radiotherapy regimens. Clinical Oncology, 5 (4), pp. 228-233
- Waymont, B., Lynch, T. H., Dunn, Janet A., Bathers, S., Wallace, D. M. A., 1993. Treatment Preferences of urologists in Great Britain and Ireland in the management of prostate cancer. British Journal of Urology, 71 (5), pp. 577-582
- Deakin, M., Gunson, B. K., Dunn, Janet A., McMaster, P., Tisone, G., Warwick, Jane, Buckels, J. A., 1993. Factors influencing blood transfusion during adult liver transplantation. Annals of The Royal College of Surgeons of England, 75 (5), pp. 339-344
- Finn, C. B., Dunn, Janet A., Buxton, E. J., Luesley, D. M., Shafi, M., 1993. Can we predict a high risk group in ovarian cancer?. International Journal of Gynecological Cancer, 3 (4), pp. 226-230
- Shafi, M. I., Dunn, Janet A., Buxton, E. J., Finn, C. B., Jordan, J. A., Luesley, D. M., 1993. Abnormal cervical cytology following large loop excision of the transformation zone : a case controlled study. Obstetrical and Gynecological Survey, 48 (8), pp. 546-548
- Blomfield, P. I., Buxton, J., Dunn, Janet A., Luesley, D. M., 1993. Pregnancy outcome after large loop excision of the cervical transformation zone. American Journal of Obstetrics and Gynecology, 169 (3), pp. 620-625
- de Takats, P. G., Dunn, Janet A., Kerr, D. J., Morrison, J. M., 1993. Impact of adjuvant chemotherapy in breast cancer on response to tamoxifen at relapse. Cancer Treatment Reviews, 19 (Supplement B), pp. 11-19
- Brown, R. D., Joshua, D. E., Nelson, M., Gibson, J., Dunn, Janet A., MacLennan, I. C. M., 1993. Serum thymidine kinase as a prognostic indicator for patients with multiple myeloma : results from the MRC (UK) V Trial. British Journal of Haematology, 84 (2), pp. 238-241
- Waymont, B., Lynch, T. H., Dunn, Janet A., Emtage, L. A., Arkell, D. G., Wallace, D. M. A., Blackledge, G. R. P., 1992. Phase III randomised study of Zoladex versus Stilboestrol in the treatment of advanced prostate cancer. British Journal of Urology, 69 (6), pp. 614-620
- MacLennan, I. C. M., Chapman, C., Dunn, Janet A., Kelly, K., 1992. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Lancet, 339 (8787), pp. 200-205
- Ward, L. C., Fielding, J. W. L., Dunn, Janet A., 1992. The selection of cases for randomised trials : a registry survey of concurrent trial and non-trial patients. British Journal of Cancer, 66 (5), pp. 943-950
- Lynch, T. H., Waymont, B., Dunn, Janet A., Wallace, D. M. A., 1992. Urologists' attitudes to the management of bladder cancer. British Journal of Urology, 70 (5), pp. 522-525
- Oláh, K. S., Dunn, Janet A., Gee, H., 1992. Leiomyosarcomas have a poorer prognosis than mixed mesodermal tumours when adjusting for known prognostic factors : the result of a retrospective study of 423 cases of uterine sarcoma. BJOG: An International Journal of Obstetrics & Gynaecology, 99 (7), pp. 590-594
- Finn, C. B., Luesley, D. M., Buxton, E. J., Blackledge, G. R., Kelly, K., Dunn, Janet A., Wilson, S., 1992. Is stage I epithelial ovarian cancer over-treated both surgically and systematically? Results of a five-year cancer registry review. Obstetrical and Gynecological Survey, 47 (7), pp. 491-493
- Finn, Catherine B., Luesley, D. M., Buxton, E. J., Blackledge, G. R., Kelly, K., Dunn, Janet A., Wilson, S., 1992. Is Stage I epithelial ovarian cancer overtreated both surgically and systemically? Results of a five-year cancer registry review. BJOG: An International Journal of Obstetrics and Gynaecology, 99 (1), pp. 54-58
- Shafi, M. I., Finn, C. B., Luesley, D. M., Jordan, J. A., Dunn, Janet A., 1991. Lesion size and histology of atypical cervical transformation zone. BJOG: An International Journal of Obstetrics & Gynaecology, 98 (5), pp. 490-492
- Finn, C. B., Ward, K., Luesley, D. M., Dunn, Janet A., Redman, C. W. E., 1991. Qualitative and quantitative analysis of peritoneal fluids from women with gynecologic diseases. Comparison of cytology and flow cytometry for the detection of malignancy in lavage and ascitic fluids. Analytical and Quantitative Cytology and Histology, 13 (3), pp. 182-186
- Oláh, K. S., Gee, H., Blunt, S., Dunn, Janet A., Kelly, K., Chan, K. K., 1991. Retrospective analysis of 318 cases of uterine sarcoma. European Journal of Cancer and Clinical Oncology, 27 (9), pp. 1095-1099
- Lynch, T. H., Waymont, B., Beacock, C. J. M., Dunn, Janet A., Hughes, M. A., Wallace, D. M. A., 1991. Follow up after transurethral resection of prostate : who needs it?. British Medical Journal, 302 (6767)
- Valori, R. M., Hallisey, M. T., Dunn, Janet A., 1990. Power of oesophageal peristalsis can be controlled voluntarily. Gut, 32 (3), pp. 236-239
- Berisa, F., Beaman, M., Adu, D., McGonigle, R. J. S., Michael, J., Downing, R., Fielding, J. W. L., Dunn, Janet A., 1990. Prognostic factors in acute renal failure following aortic aneurysm surgery. QJM, 76 (1), pp. 689-698
- Wallace, D. M. A., Raghavan, D., Kelly, K. A., Sandeman, T. F., Conn, I. G., Teriana, N., Dunn, Janet A., Boulas, J., Latief, T., 1990. Neo-adjuvant (pre-emptive) Cisplatin therapy in invasive transitional cell carcinoma of the bladder. British Journal of Urology, 67 (6), pp. 608-615
- Friede, Tim, Dunn, Janet A., Stallard, Nigel, 2008. Clinical trials in oncology. In Missailidis, Sotiris (ed.), Anticancer therapeutics, Oxford ; Hoboken, NJ, Wiley-Blackwell, pp. 365-375
- Young, Annie M., Phillips, J., Marshall, A., Grumett, J., Dunn, Janet A., Lowe, S., Chapman, O., Lokare, A., 2014. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. 7th ITHIC, Published in Thrombosis Research, pp. S220-S220
- Meads, D. M., McCabe, C., Hulme, C. T., Edlin, R., Kharroubi, S. A., Browne, C., Ford, H., Dunn, Janet A., Marshall, A., 2014. Cost-utility of cancer therapies - the 'cost' of different utility generation strategies. ISPOR 17th Annual European Congress, Amsterdam, The Netherlands, 08 - 12 Nov 2014, Published in Value in Health: The Journal of The International Society for Pharmacoeconomic and Outcomes Research
- Balmer, Claire E., Dunn, Janet A., Griffiths, Frances, 2012. Using photographs to describe what it's like to live with and beyond cancer. INVOLVE 2012 conference, East Midlands Conference Centre, Nottingham, 13-14 Nov 2012
- Balmer, Claire E., Dunn, Janet A., Griffiths, Frances, 2010. How does contemporary health care meet the needs of those living with a poor prognostic cancer and does it need improving?. ESRC Research Methods Conference
- Balmer, Claire E., Dunn, Janet A., Griffiths, Frances, 2010. Using photography to find out about the needs of often neglected populations. INVOLVE Conference 2010, 2010
- Dunn, Janet A., Wilcox, M., Taggart, Frances M., Hulme, Claire, Tritter, Jonathan, Austoker, Joan, Mossman, Jean, Fide, Jane, Balmer, Claire E., Beaver, Kinter, Donnelly, Peter, 2009. Involving patients in clinical trial design : the experience of the UK Ibreast early breast cancer follow-up trial. Society for Clinical Trials Annual 30th Annual Meeting 2009, Atlanta, Georgia, USA, 2009
- Bartlett, J. M. S., Munro, A., Dunn, Janet A., Hiller, Louise, Jordan, S., Twelves, Chris, Cameron, D. A., Thomas, J., Campbell, F., Rea, D. W., Provenzano, E., Pharoah, P., Caldas, Carlos, Earl, Helena M., Poole, Christopher J., 2009. Chromosome 17 polysomy (Ch17) as a predictor of anthracycline response: emerging evidence from the UK NEA Tadjuvant breast cancer trial. 31st Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 10-14, 2008, Published in Cancer Research, pp. 74S-74S
- Spooner, David A., Stocken, D. D., Jordan, S., Bathers, S., Dunn, Janet A., Jevons, C., Morrison, M., Oates, G., Grieve, R., 2009. A randomised controlled trial to evaluate both the role and optimal fractionation of radiotherapy in the conservative management of early breast cancer.. 31st Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 10-14, 2008, Published in Cancer Research, pp. 338S-338S
- Bartlett, J. M. S., Munro, A., Desmedt, Christine, Dunn, Janet A., Larsimont, D., O'Malley, F. P., Cameron, D. A., Earl, Helena M., Poole, Christopher J., Shepherd, Lois, Cardoso, Fatima, Caldas, Carlos, Twelves, Chris, Pritchard, K., Rea, D. W., di Leo, A., 2009. Duplication of chromosome 17 CEP predicts for anthracycline benefit: a meta-analysis of 4 trials. 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, DEC 09-13, 2009, Published in Cancer Research, pp. 716S-716S
- Biswas, S., East, C., A'Hern, A., Marshall, A. (Andrea), Dunn, Janet A., Lorigan, Paul, Middleton, M. (Mark), Corrie, P., 2008. Adjuvant bevacizumab is safe treatment for melanoma patients at high risk of recurrence. 33rd European Society for Medical Oncology Congress, Stockholm, Sweden, 12-16 Sept 2008, Published in Annals of Oncology, pp. 245-246
- Dunn, Janet A., Balmer, Claire E., McConkey, Christopher C., Nutting, Chris, Fisher, Sheila, Wong, Wai Lup, MacLennan, Ken, McCabe, Chris, Hulme, Claire, Mehanna, Hisham M., 2008. PET-NECK : setting up a collaborative clinical trial in a rare disease site. Society for Clinical Trials Annual Meeting 2008
- Ishak, K., Deniz, B., Drayson, Mark T., Morgan, G. J., Augustson, B., Child, A., Begum, Gulnaz, Dunn, Janet A., Shearer, Arran, Caro, J. Jaime, 2008. Modeling overall survival in the event of patient cross-over from dexamethasone to lenalidomide in phase III multiple myeloma trials. 48th Annual Scientific Meeting of the British-Society-for-Haematology, Glasgow, Scotland, Apr 07-09, 2008, Published in British Journal of Haematology, pp. 121-121
- Midgley, Rachel S. J., McConkey, Christopher C., Langman, Michael J., Smith, Justine L., Julier, Patrick, Iveson, Claire, Johnstone, Elaine, Chen, Xiao-he, Dunn, Janet A., Kerr, David J., 2008. VICTOR : a phase III placebo-controlled trial of rofecoxib in colorectal cancer patients following surgical resection. 33rd European Society for Medical Oncology Congress, Stockholm, Sweden, 12-16 Sept 2008, Published in Annals of Oncology, pp. 1-1
- Drayson, M. T., Augustson, B. M., Begum, G., Dunn, Janet A., Barth, N. J., Davies, F., Morgan, G., Behrens, J., Smith, A., Child, J. A., 2007. Survival from relapse and the influence of therapy. 11th International Myeloma Workshop/4th International Workshop on Wladenestroms Macroglobulinemia, Kos Isl, Greece, June 25-30, 2007, Published in Haematologica, pp. 173-173
- Hiller, Louise, Fenwick, N., Vallier, A. L., Dunn, Janet A., Hilborne, S., Jones, L., Abraham, J., Iddawela, M., Caldas, Carlos, Earl, Helena M., 2007. The challenges of using radiological 'tumour response' as an endpoint in Neo-tAnGo: a national neo-adjuvant chemotherapy breast cancer trial. 10th Nottingham International Breast Cancer Conference, Nottingham, England, September 18-20, 2007, Published in European Journal of Cancer Supplements, pp. 33-34
- Poole, C. J., Hiller, Louise, Howard, H. C., Loi, Shrushma, Dunn, Janet A., Canney, P., Wardley, A. M., Crown, J. P., Coleman, R. E., Verrill, M. W., Ellis, P. A., Leonard, R. C., Spooner, David A., Earl, Helena M., 2006. Tolerability of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy in the randomized phase III tAnGo trial for invasive higher risk early stage breast cancer.. 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, DEC 14-17, 2006, Published in BREAST CANCER RESEARCH AND TREATMENT, pp. S114-S114
- Fielding, J. W. L., Dunn, Janet A., Baker, P. G., Davis, J. G., Billingham, L. J., Hallisey, M. T., Langham, M. J., 1997. An interim report of the cimetidine therapy in stomach cancer (CIS) study. GI Cancer
- Jones, Lyn I., Taylor-Phillips, Sian, Geach, Rebecca, Harding, Sam A., Marshall, ?A., McKeown-Keegan, Sadie, Dunn, Janet A., 2022. Re: The potential of abbreviated breast MRI (FAST MRI) as a tool for breast cancer screening : a systematic review and meta-analysis. A reply. Clinical Radiology, W.B. Saunders Co. Ltd, pp. 73-75
- Atkin, C., Drayson, M., Iqbal, Gulnaz, Yong, K., Pratt, G., Planche, T., Wood, J., Raynes, K., Higgins, Helen B., Dunn, Janet A., Bowcock, S., 2018. Presenting symptoms of patients with multiple myeloma : data from the TEAMM (Tackling EArly Morbidity and Mortality in Myeloma) trial. British Journal of Haematology, Wiley, pp. 5-211
- Stein, R. C., Makris, A., Hughes-Davies, L., Macpherson, I. R., Hall, P. S., Cameron, D. A., Earl, H. M., Pinder, S. E., Poole, C. J., Rea, D. W., McIntosh, S., Harmer, V., Morgan, A., Rooshenas, L., Conefrey, C., Donovan, J. L., Hulme, C, McCabe, Chris, Stallard, Nigel, Campbell, A. et al (Select to open full list), 2018. OPTIMA : A prospective randomized trial to validate the predictive utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in early breast cancer. Cancer Research, American Association of Cancer Research
- Bowcock, S., Atkin, C., Iqbal, Gulnaz, Yong, K., Pratt, G., Planche, T., Wood, J., Raynes, K., Hawkey, P., Dunn, Janet A., Drayson, M., Co-Investigators, Teamm, 2018. Does a long diagnostic pathway in myeloma lead to more advanced disease at presentation? An analysis from the TEAMM trial (Tackling EArly Morbidity and Mortality in Myeloma). British Journal of Haematology, Wiley, pp. 5-211
- Chicca, I. J., Heaney, J. L. J., Iqbal, Gulnaz, Bowcock, S., Planche, T., Wood, J., Raynes, K., Hawkey, P., Pratt, G., Yong, K., Dunn, Janet A., Drayson, M. T., 2018. Major changes in levels of regulatory cytokines and functional antibodies contribute to severe immunodeficiency of myeloma patients and persist at one year post diagnosis. Haematologica, Fondazione Ferrata Storti, pp. 1-48
- Young, Annie M., Marshall, A. (Andrea)?, Thirlwall, Jenny, Chapman, O., Lokare, A., Hills, Claire E., Hale, D., Dunn, Janet A., Kakkar, A., Levine, M., Select-d Collaborative, Group, 2018. Anticoagulation therapy in SELECTeD cancer patients at risk of recurrence of venous thromboembolism : results of the 'select-d' Pilot Trial. Thrombosis Research, Pergamon-Elsevier Science Ltd
- Bowcock, S., Planche, T., Iqbal, Gulnaz, Pratt, G., Yong, K., Wood, J., Raynes, K., Hawkey, P., Dunn, Janet A., Drayson, M., Co-Investigators, Teamm, 2018. Levofloxacin prophylaxis in newly diagnosed myeloma reduces febrile episodes and death without increasing healthcare associated infections : results from the TEAMM trial (Tackling EArly Morbidity and Mortality in Myeloma). British Journal of Haematology, Wiley, pp. 5-211
- Dunn, Janet A., Marshall, A. (Andrea)?, Ramirez, M., Evans, A., Donnelly, P., 2017. Value of a sister observational cohort alongside a randomised controlled trial with an internal feasibility phase. Trials, Biomed Central Ltd
- Mistry, Pankaj, Dunn, Janet A., Marshall, A. (Andrea)?, 2017. A literature review of the use of adaptive design methods in oncology trials. Trials, Biomed Central Ltd
- Morgan, A., Ah-See, M. L., Hunter, M., Armes, J., Filshie, J., Turner, L., Morris, C., Flint, M., Dunn, Janet A., Pennery, E., Sassarini, J., Stanway, S., Noble, J., Andreia, F., Morgan, D., Khambhaita, P., Fenlon, D., 2017. Comparing clinician and patient perspectives in the management of hot flushes in UK breast cancer patients. BJOG-an International Journal of Obstetrics and Gynaecology, Wiley, pp. 100-102
- Taylor-Phillips, Sian, Jenkinson, David J., Wallis, Matthew, Dunn, Janet A., Clarke, Aileen, 2017. Pragmatic integrated randomised controlled trials in screening : experience from a trial in 1.2million women attending breast screening. Trials, Biomed Central Ltd
- Wong, W. L., Dunn, Janet A., Mehanna, H., 2016. The role of PET CT in the management of advanced nodal head neck cancer post chemoradiotherapy. Translational Cancer Research, AME Publishing Company, pp. S932-S932
- Mehanna, H., Wong, W. L., Dunn, Janet A., 2016. Management of Advanced Head and Neck Cancer REPLY. New England Journal of Medicine, Massachusetts Medical Society, pp. 492-493
- Smith, A. F., Hall, P. S., Hulme, Charles, McConkey, Christopher C., Dunn, Janet A., Rahman, J., Mehanna, H., 2016. PET-CT surveillance for advanced head and neck cancer : a cost-effective alternative to planned neck dissection?. Annals of Oncology, Oxford University Press
- Rea, D., Francis, A., Poole, C., Brookes, C., Stein, R., Bartlett, J., Dunn, Janet A., Canney, P., Sutton, R., Daoud, R., Hallissey, M., Achuthan, R., Grant, M., Babrah, J., Smith, S., Fraser, J., Desai, A., Al Dubaisi, M., Patel, A., Bristol, J. et al (Select to open full list), 2016. NEO-EXCEL phase III neoadjuvant trial of pre-operative exemestane or letrozole plus /- celecoxib in the treatment of ER positive postmenopausal early breast cancer. Cancer Research, American Association of Cancer Research
- Mehanna, H., Wong, W. L., Dunn, Janet A., 2016. Management of advanced nodal disease in patients treated with primary chemoradiotherapy. Current Opinion in Oncology, Lippincott Williams and Wilkins, pp. 201-204
- Mehanna, H., Franklin, N., Compton, N., Robinson, M., Powell, N., Biswas-Baldwin, N., Paleri, V., Hartley, A., Fresco, L., Al-Booz, H., Junor, E., El-Hariry, I., Roberts, S., Harrington, K., Ang, K. K., Dunn, Janet A., Woodman, C., 2016. Geographic variation in human papillomavirus-related oropharyngeal cancer : data from 4 multinational randomized trials. Head and Neck, John Wiley and Sons Inc, pp. E1863-E1869
- Stein, R. C., Makris, A., Hughes-Davies, L., Bartlett, J. M. S., Marshall, A. (Andrea)?, Hall, P. S., Campbell, A., Pinder, S. E., Cameron, D. A., Rea, D., Earl, H., MacPherson, I., Poole, C., Canney, P., Francis, A., Morgan, A., Stallard, Nigel, Hulme, C., McCabe, C., Dunn, Janet A., 2015. Results of the OPTIMA (Optimal Personalized Treatment of early breast cancer usIng Multi-parameter Analysis) prelim study. European Journal of Cancer Care, Wiley-Blackwell Publishing Ltd
- Mehanna, H., Wong, W. L., McConkey, Christopher C., Rahman, J. K., Robinson, M., Hartley, A., Nutting, C., Powell, N., Al-Booz, H., Robinson, M., Junor, E., Hulme, C., Smith, A. F., Hall, P., Dunn, Janet A., 2015. Differences in the quality of life (QoL) and functional outcomes of treatment between HPV associated (HPV plus ) and HPV-patients receiving primary chemoradiotherapy in PET-NECK - a multi-centre randomized phase III controlled trial (RCT) comparing PETCT guided active surveillance with planned neck dissection (ND) for locally advanced (N2/N3) nodal metastases (LANM) in patients with head and neck squamous cell cancer (HNC) treated with primary radical chemoradiotherapy (CRT). European Journal of Cancer, Elsevier Science Ltd
- Smith, A. F., Hall, P., Hulme, C., Dunn, Janet A., Rahman, J. K., McConkey, Christopher C., Mehanna, H., 2015. Is PET-CT guided management for patients with locally advanced head and neck squamous cell cancer (HNSCC) cost-effective? Results from a UK non-inferiority phase III randomized trial. Journal of Clinical Oncology, American Society of Clinical Oncology, pp. 6010-6010
- Mehanna, H. M., Wong, W. L., McConkey, Christopher C., Rahman, J. K., Robinson, M., Hartley, A. G. J., Nutting, C., Powell, N., Al-Booz, H., Robinson, M., Junor, E., Hulme, C., Smith, A. F., Hall, P., Dunn, Janet A., 2015. PET-NECK: A multi-centre, randomized, phase III, controlled trial (RCT) comparing PETCT guided active surveillance with planned neck dissection (ND) for locally advanced (N2/N3) nodal metastases (LANM) in patients with head and neck squamous cell cancer (HNSCC) treated with primary radical chemoradiotherapy (CRT). Journal of Clinical Oncology, American Society of Clinical Oncology, pp. 6009-6009
- Young, Annie M., Phillips, Jessica M., Hancocks, H., Marshall, A. (Andrea)?, Grumett, J., Dunn, Janet A., Chapman, Oliver, 2015. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Journal of Clinical Oncology, American Society of Clinical Oncology
- Hall, P., Smith, A., Hulme, C., Vargas-Palacios, A., Dunn, Janet A., Marshall, A. (Andrea)?, Bartlett, J., Stein, R., Cameron, D., McCabe, C., 2015. The use of early decision modelling and value of information analysis in an adaptive trial design : results from the OPTIMA preliminary study. Trials, Biomed Central Ltd
- Mistry, Pankaj, Hiller, Louise, Iqbal, Gulnaz, Dunn, Janet A., 2015. Under-representation of male patients in breast cancer studies. Trials, Biomed Central Ltd
- Bartlett, J. M. S., Stein, R. C., Bayani, J., Marshall, A. (Andrea)?, Dunn, Janet A., Campbell, A. F., Cunningham, C., Sobol, M., Hall, P., Rooshenas, L., Morgan, A., Poole, Christopher J., Pinder, S. E., Cameron, D. A., Stallard, Nigel, Donovan, J., McCabe, C., Hughes-Davies, L., Makris, A., 2015. Comparison of multiparameter tests in the UK OPTIMA-Prelim trial. Cancer Research, American Association of Cancer Research
- Hiller, Louise, Marshall, A. (Andrea)?, Dunn, Janet A., 2015. Assessing violations of the proportional hazards assumption in Cox regression : does the chosen method matter?. Trials, Biomed Central Ltd
- Dunn, Janet A., Marshall, A. (Andrea)?, Campbell, Amy, Cameron, D., Earl, H., Macpherson, I., Poole, C., Rea, D., Francis, A., Harmer, V., Morgan, A., Stallard, Nigel, Makris, A., Hughes-Davies, L., Stein, R., 2015. Practicalities of using an adaptive design for decision making within the optima trial : optimal personalized treatment of early breast cancer using multi-parameter tests. Trials, Biomed Central Ltd
- Dunn, Janet A., Harris, B., Iqbal, Gulnaz, Wood, J., Mistry, Pankaj, O'Beirne-Elliman, J., Bowcock, S., Drayson, M., 2015. Use of patient diaries in conjunction with standard reporting methods : duplication of data or a valuable resource?. Trials, Biomed Central
- Ah-See, M., Coles, C., Fenlon, D., Pennery, E., Dunn, Janet A., Morgan, A., 2014. The current management of vasomotor symptoms in breast cancer patients in the UK : clinician versus patient perspective. NCRI Breast CSG Working Party on Symptom Management (Vasomotor). European Journal of Cancer, Elsevier, pp. S88-S89
- Young, Annie M., Dunn, Janet A., Chapman, O., Grumett, J., Marshall, A., Phillips, J., Lokare, A., 2014. SELECT-D : anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. Journal of Clinical Oncology, American Society of Clinical Oncology
- Hiller, Louise, Vallier, A. L., Ogburn, E., Wardley, A. M., Cameron, D. A., Miles, D., Dunn, Janet A., Earl, H. M., 2014. Cardiology monitoring substudy in the PERSEPHONE trial : 6 versus 12 months of trastuzumab. Journal of Clinical Oncology, American Society of Clinical Oncology
- Earl, H. M., Cameron, D. A., Miles, D., Wardley, A. M., Ogburn, E., Vallier, A. L., Loi, S., Higgins, H. B., Hiller, Louise, Dunn, Janet A., 2013. PERSEPHONE : duration of trastuzumab with chemotherapy in women with HER2-positive early breast cancer-six versus twelve months. Journal of Clinical Oncology, American Society of Clinical Oncology
- Earl, H. M., Chin, S. F., Dunning, M., Iddawela, M., Rueda, O., Russell, R., Jones, L., Vallier, A. L., Hughes-Davies, L., Abraham, J., Chan, S., Skene, A., Benstead, K., Gallagher, C. J., Murray, N., Ritchie, D., Dunn, Janet A., Hiller, Louise, Provenzano, E., Caldas, C., 2013. Neo-tAnGo science : a translational study of PAM 50 sub-typing in sequential fresh tissue samples during neoadjuvant chemotherapy. Journal of Clinical Oncology, American Society of Clinical Oncology
- Corrie, P., Marshall, A. (Andrea)?, Goonewardena, M., Dunn, Janet A., Middleton, M. R., Nathan, P. D., Gore, M. E., Davidson, N., Nicholson, S., Kelly, C. G., Marples, M., Danson, S., Marshall, E., Houston, S., Board, R. E., Waterston, A. M., Nobes, J., Harries, M., Barber, J., Lorigan, P., 2013. Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence : preplanned interim results for the AVAST-M trial. Journal of Clinical Oncology, American Society of Clinical Oncology
- Ford, H., Marshall, A. (Andrea)?, Wadsley, J., Coxon, F. Y., Mansoor, W., Bridgwater, J. A., Madhusudan, S., Falk, S., Middleton, G. W., Swinson, D., Chau, I., Thompson, J., Blazeby, J. M., Cunningham, D., Kareclas, P., Dunn, Janet A., 2013. COUGAR-02 : a randomized phase 111 study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma. Journal of Clinical Oncology, American Society of Clinical Oncology
- Morgan, A., Fenlon, D., Coles, C., Armstrong, A., Randle, K., Thompson, A., Dunn, Janet A., 2013. Is it me or is it hot in here? Hot flushes (or flashes) : an unmet need. UK NCRI breast clinical studies group working party on symptom management (vasomotor). Cancer Research, American Association of Cancer Research
- McCaul, J. A., Pendrill, A., Quantrill, J., Mehanna, H., McConkey, Christopher C., Dunn, Janet A., 2013. LIHNCS trial (Lugol's iodine in head and neck cancer surgery) : Interim recruitment and data report. Oral Oncology, Elsevier BV, pp. S37-S37
- McCaul, J. A., Cymerman, J., Sutton, D. N., Shaw, R. J., Hislop, S., Adamson, J., Dunn, Janet A., 2013. Feasibility and surgeon acceptability of visualisation with Lugol's iodine (VILI) in the lihncs trial. Oral Oncology, Elsevier BV, pp. S35-S35
- Corrw, P., Marshall, A. (Andrea)?, Goonewardena, M., Dunn, Janet A., Middleton, M. R., Nathan, P. D., Gore, M. E., Davidson, N., Nicholson, S., Kelly, C. E. G., Marples, M., Damson, S., Marshall, E., Houston, S., Board, R. E., Waterston, A. M., Nobes, J., Harries, M., Barber, J., Lorigan, P., 2013. AVAST-M: Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence. Journal of Clinical Oncology, American Society of Clinical Oncology
- Earl, H. M., Vallier, A. L., Ogburn-Storey, E., Cameron, D. A., Wardley, A. M., Miles, D., Loi, S., Hiller, Louise, Higgins, H. B., Dunn, Janet A., 2013. PERSEPHONE : duration of trastuzumab with chemotherapy in women with HER-2+ve early breast cancer. Cancer Research, American Association of Cancer Research
- Earl, H. M., Blenkinsop, C., Grybowicz, L., Vallier, A. L., Cameron, D. A., Bartlett, J. M. S., Murray, N., Caldas, C., Thomas, J., Dunn, Janet A., Higgins, H. B., Hiller, L., Hayward, L., 2012. ARTemis trial - randomised trial with neo-adjuvant chemotherapy for patients with early breast cancer. Journal of Clinical Oncology, American Society of Clinical Oncology
- Abdelaziz, M., Marshall, A. (Andrea)?, Hussain, K., Bradley, A., Agostini, P., Bishay, E., Kalkat, M., Steyn, R., Rajesh, P., Dunn, Janet A., Naidu, B., 2012. Can the thoracoscore and revised cardiac risk index predict outcomes?. Lung Cancer, Elsevier
- Parsons, A., Bradley, A., Reaper, L., Jordan, C., Paul, A., Dowswell, G., Dunn, Janet A., Naidu, B., 2012. Patient's experiences of a pre and post surgery rehabilitation programme for lung cancer (Rehabilitation Of lung Cancer (ROC) programme) : a qualitative interview study. Lung Cancer, Elsevier Ireland LTD, pp. S64-S64
- Earl, H. M., Cameron, D. A., Miles, D., Wardley, A. M., Ogburn, E. R. M., Vallier, A. L., Loi, S., Higgins, H. B., Hiller, L., Dunn, Janet A., 2012. PERSEPHONE : duration of trastuzumab with chemotherapy in women with HER2 positive early breast cancer. Cancer Research, American Association for Cancer Research
- Dunn, Janet A., Kulkarni, R., Gouldesbrough, D., Mehanna, H., McMahon, J. M., Shaw, R., McCaul, J. A., 2012. LIHNCS trial : Lugol's iodine in head and neck cancer surgery. Journal of Clinical Oncology, American Society of Clinical Oncology
- Poole, Christopher J., Marshall, A. (Andrea)?, Higgins, Helen B., Fletcher, J., Williams, S. J., Lo, N., Fernando, I. N., Osborne, R., Crawford, S. M., Rafii, S., Gill, S., Dunn, Janet A., 2012. Neo-escape : Neoadjuvant extended sequential chemotherapy with adjuvant postoperative treatment for epithelial nonmucinous advanced inoperable peritoneal malignancy. Journal of Clinical Oncology, American Society of Clinical Oncology
- Earl, H. M., Cameron, D. A., Miles, D., Wardley, A. M., Ogburn, E., Vallier, A. L., Loi, S., Higgins, H. B., Hiller, L., Dunn, Janet A., 2012. The PERSEPHONE trial : duration of trastuzumab with chemotherapy in women with HER2-positive early breast cancer. Journal of Clinical Oncology, American Society of Clinical Oncology
- Stein, R., Makris, A., Hughes-Davies, L., Dunn, Janet A., Bartlett, J. M. S., Donovan, J., McCabe, C., Cameron, D. A., Canney, P., Earl, H. M., Francis, A., Morgan, A., Pinder, S., Rea, D., Poole, C. J., Hall, P., Hiller, L., Stallard, Nigel, Higgins, H. B., 2012. OPTIMA prelim : optimal personalized treatment of early breast cancer using multiparameter analysis : preliminary study. Journal of Clinical Oncology, American Society of Clinical Oncology
- Marshall, A. (Andrea), Dunn, Janet A., Fletcher, Julie, Higgins, Helen B., Poole, Christopher, 2011. The importance of planning for a seamless transition in an adaptive phase II randomised trial. Trials, Bio Med Central
- Ali, A. M. G., Provenzano, E., Abraham, J., Bartlett, J. M., Poole, C. J., Hiller, L., Dunn, Janet A., Twelves, C., Earl, H. M., Caldas, C., Pharoah, P., 2011. Prognosis by breast cancer subtypes in patients treated with adjuvant chemotherapy in a clinical trial. Journal of Clinical Oncology, American Society of Clinical Oncology
- Earl, H. M., Loi, S., Vallier, A. L., Hiller, L., Ogburn-Storey, E., Higgins, H., Dunn, Janet A., 2011. The PERSEPHONE trial : duration of trastuzumab with chemotherapy in women with HER2 positive early breast cancer. Changing the randomisation point to address potential barriers to recruitment. Cancer Research, American Association for Cancer Research
- Morgan, G. J., Knight, R. D., Ishak, K. J., Drayson, M. T., Dimopoulos, M. A., Weber, D. M., Augustson, B., Child, J. A., Begum, G., Dunn, Janet A., Shearer, A., Caro, J. J., 2009. Addressing biased survival due to crossover in trials. Clinical Lymphoma & Myeloma, Elsevier, pp. S50-S51
- Wong, Wai Lup, Nutting, Chris, Dunn, Janet A., Fisher, Sheila, MacLennan, Ken, MacCabe, Chris, Mehanna, Hisham M., 2009. Advanced head and neck cancer: is there a role for fluorodeoxyglucose PET/computed tomography?. Nuclear Medicine Communication, Lippincott Williams & Wilkins, pp. 2-4
- Biswas, S., East, C., A'Hern, A., Marshall, A., Dunn, Janet A., Lorigan, P., Middleton, M., Corrie, P., 2008. Adjuvant bevacizumab for melanoma patients at high risk of recurrence : survival analysis of the AVAST-M trial. Annals of Oncology, Oxford University Press, pp. 245-245
- Ishak, K. J., Deniz, B., Drayson, M., Morgan, G. J., Augustson, B. M., Child, J. A., Begum, G., Dunn, Janet A., Shearer, A., Caro, J. J., 2008. A novel approach to adjust for the impact on survival resulting from patient cross-over from control to experimental treatment in clinical trials. Value in Health, Wiley-Blackwell Publishing, Inc, pp. A155-A155
- Donnelly, Peter K., Hiller, Louise, Dunn, Janet A., 2008. Follow-up after breast cancer : national randomised controlled trial is needed. British Medical Journal, B M J Publishing Group, pp. 461-462
- Donnelly, Peter K., Hiller, Louise, Dunn, Janet A., 2008. Need for the iBreast trial ? risk adjusted breast cancer follow-up trial. BMJ, BMJ Publishing Group Ltd
- Kerr, David J., Dunn, Janet A., Langman, Michael J., Smith, J. L., Midgley, Rachel S. J., Iveson, Claire, McConkey, Christopher C., 2008. VICTOR : a phase III placebo-controlled trial of rofecoxib in colorectal cancer patients following surgical resection. Journal of Clinical Oncology, American Society of Clinical Oncology
- Neoptolemos, J. P., Raraty, M. G. T., Ghaneh, P., Hickey, H., Stocken, D. D., Dunn, Janet A., Friess, H., Buchler, M. W., Schemmer, P., 2003. Adjuvant and additive therapy for cancer of the pancreas. Der Chirurg, Springer-Verlag, pp. 191-201
- Neoptolemos, J. P., Cunningham, D., Friess, H., Bassi, C., Stocken, D. D., Tait, D. M., Dunn, Janet A., Dervenis, C., Lacaine, F., Hickey, H., Raraty, M. G. T., Ghaneh, P., Büchler, M. W., 2003. Adjuvant therapy in pancreatic cancer : historical and current perspectives. Annals of Oncology, Oxford University Press, pp. 675-692
- Neoptolemos, J. P., Stocken, D., Dunn, Janet A., 2002. Letter to the editor 2 (multiple letters). Annals of Surgery, Lippincott Williams & Wilkins, pp. 696-697
- Neoptolemos, J. P., Stocken, D. D., Dunn, Janet A., Almond, J., Beger, H. G., Pederzoli, P., Bassi, C., Dervenis, C., Fernandez-Cruz, L., Lacaine, F., Buckels, J., Deakin, M., Adab, F. A., Sutton, R., Imrie, C., Ihse, I., Tihanyi, T., Olah, A., Pedrazzoli, S., Spooner, D. et al (Select to open full list), 2001. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Annals of Surgery, Lippincott Williams & Wilkins, pp. 758-768
- Drayson, M. T., Chapman, C. E., Olujohungbe, A., Dunn, Janet A., Maclennan, I. C. M., 1998. The MRC randomised trial of the use of a2b-interferon in first plateau phase in multiple myeloma. Cancer Research Therapy and Control
- Dunn, Janet A., 1994. Seventeenth sir peter freyer memorial lecture and surgical symposium -September 18th & 19th, 1992. Irish Journal of Medical Science, pp. 68-92
- Clarke, M., Gray, R., Dunn, Janet A., Maclennan, I., 1992. Combination chemotherapy for myelomatosis. The Lancet
- Dunn, Janet A., 1992. Prognostic indices : who needs them?. Controlled Clinical Trials, Elsevier, pp. 381-382
- Dunn, Janet A., Hallissey, M. T., 1992. Developing a prognostic index for stomach cancer. Controlled Clinical Trials, Elsevier
- Dunn, Janet A., MacLennan, I., 1992. Comparing trials for the treatment of myelomatosis. Controlled Clinical Trials, Elsevier
Title | Funder | Award start | Award end |
---|---|---|---|
NIHR HTA via Derby NHS Tust: ATNEC?Axillary management in T1-3N1M0 breast cancer patients with FNA or core biopsy proven nodal metastases at presentation after NEoadjuvant Chemotherapy | National Institute for Health Research (DoH) | 01 Mar 2020 | 28 Feb 2030 |
ATNEC Y6-10 | National Institute for Health Research (DoH) | 01 Mar 2020 | 28 Feb 2030 |
NIHR HTA Stage 2 via UHCW: Evaluation of PeRsOnalised PrEhabilitation in acute myeloid Leukaemia (PROPEL). | National Institute for Health Research (NIHR DoH) | 01 Sept 2022 | 31 Aug 2027 |
NIHR EME NIHR150502 via Bristol: : Diagnostic yield study to determine whether an abbreviated form of breast Magnetic Resonance Imaging (FAST MRI) can detect breast cancers missed by screening mammography for women at population risk of breast cancer with average mammographic density following their initial screening mammogram | National Institute for Health Research (NIHR DoH) | 01 May 2023 | 31 Oct 2026 |
Mammo-50: Access to NHS Breast Screening Programme Data (NHS BSP) linked to IDEATE 72784 & 33985 | NHS England | 31 Oct 2023 | 30 Oct 2026 |
NIHR PGfAR via Newcastle: Improving outcomeS for Women diagnosed with early breast cancer through adhErence to adjuvant Endocrine Therapy (SWEET) | National Institute for Health Research (DoH) | 18 May 2020 | 17 May 2026 |
COBIx: Multi-site validation of automated AI tool for screening of large bowel endoscopic biopsy slides | National Institute for Health Research (NIHR DoH) | 01 Apr 2023 | 31 Mar 2026 |
NIHR Programme Grant:Improving outcomeS for Women diagnosed with early breast cancer through adhErence to adjuvant Endocrine Therapy (SWEET) Year 6 costs | National Institute for Health Research (DoH) | 03 Feb 2020 | 02 Feb 2026 |
Bloodwise: Repurposed drugs to improve haematological responses in Myelodysplastic Syndromes (MDS) | Bloodwise | 01 Sept 2020 | 30 Jun 2025 |
NIHR HTA Stage 2: Volatile vs Total intravenous Anaesthesia for major non-cardiac surgery ? a randomised controlled triaL (VITAL) | National Institute for Health Research (NIHR DoH) | 01 Nov 2020 | 30 Apr 2025 |
Veracyte Gift award for OPTIMA Investigator Meeting | VERACYTE | 01 Feb 2024 | 31 Jan 2025 |
Make 2NDS COUNT: A national study of the experiences, information needs and attitudes to clinical research of patients living with secondary breast cancer in the UK (MSBC) | MAKE 2NDS COUNT | 01 Jan 2021 | 30 Sept 2024 |
Breast Cancer Now: Mammographic Density Study | Breast Cancer Now | 01 Mar 2019 | 31 Aug 2024 |
Mammographic surveilance in breast cancer patients aged 50 years or older (Mammo-50) (RMRCT 1081) Extension.Linked to IDEATE 33985 | National Institute for Health Research (NIHR DoH) | 01 Jul 2022 | 31 Dec 2023 |
NIHR HTA Costed Extenison: Digital Pathology_Linked to Main award on IDEATE 58038 | National Institute for Health Research (NIHR DoH) | 01 Nov 2021 | 30 Apr 2023 |
NIHR Senior Investigator Award 2018 | National Institute for Health Research (DoH) | 01 Apr 2019 | 31 Mar 2023 |
OPTIMA - 8 year extension | National Institute for Health Research (DoH) | 01 Apr 2015 | 31 Mar 2023 |
Breast Cancer Now:SENTINUS: Multicentre phase II trial to assess technical feasibility and diagnostic performance of intradermal microbubbles and contrast-enhanced ultrasound (CEUS) plus core biopsy as a test to identify sentinel lymph node (SLN) metastases in patients with primary invasive breast cancer and a normal axillary grey-scale ultrasound. Lead by Maidstone NHS Trust | Breast Cancer Now | 05 Oct 2020 | 04 Jan 2023 |
Mammographic surveillance in breast cancer patients aged 50 years or older | National Institute for Health Research (DoH) | 01 Mar 2013 | 28 Feb 2022 |
NIHR HTA: Whole slide imaging in pathology | National Institute for Health Research (DoH) | 01 Nov 2018 | 31 Oct 2021 |
PET NECK Data Re-Analysis | University of Birmingham | 01 Feb 2017 | 31 Dec 2020 |
PERSEPHONE Trial: Amendment to Collaboration agreement. Linked to IDEATE record 50306. | National Institute for Health Research (NIHR DoH) | 01 Apr 2007 | 31 Dec 2020 |
OPTIMAL study with Churchill Oxford NHS Trust | Oxford University Hospitals NHS Trust | 01 Apr 2014 | 31 Mar 2020 |
De-escalate - Extension and supplement | Cancer Research UK | 01 Sept 2017 | 31 Dec 2019 |
CRUK funded via Cambridge: AVAST-M - Extension | Cancer Research UK | 01 Aug 2010 | 31 Dec 2019 |
Persephone extension and supplement | National Institute for Health Research (DoH) | 01 Jul 2016 | 30 Jun 2019 |
Sponsorship of 2019 OPTIMA Investigator Meeting | Nanostring Technologies | 04 Apr 2019 | 03 May 2019 |
Investigating interactions between the triad of Myeloma disease activity TEAMM EME | National Institute for Health Research (DoH) | 01 Feb 2017 | 31 Jan 2019 |
ARTemis: Avastin randomised trial with nEo-adjuvant cheMotherapy for patinets with early breat cancer : Analysis Extension | Cambridge University Hospitals NHS Foundation Trust | 01 Jul 2011 | 31 Dec 2018 |
Avastin Randomised Trial with neo-adjuvant chemotherapy for patients with early HER 2 negative breast cancer Artemis Year 9 Funding - staff - Late Phase Study | Cancer Research UK | 01 May 2017 | 30 Apr 2018 |
ARTEMIS Pre-operative Avastin with neo-adjuvant chemotherapy Years 7,8 & 9 Support Funding | Cancer Research UK | 01 May 2015 | 30 Apr 2018 |
Late Phase Study De-ESCALaTE-HPV Determination of Epidermal growth factor receptor-inhibitor(cetuximab) vs Standard Chemotherapy early and late toxicity Events - Year 6 | Cancer Research UK | 01 Sept 2016 | 31 Aug 2017 |
De-ESCALaTE-HPV - TrialDetermination of epidermal growth factor receptor-inhibitor (cetuximab) vs standard chemotherapy early and late toxicity events in human papilloma virus positive oropharyngeal carcinoma | Cancer Research UK | 01 Mar 2011 | 28 Feb 2017 |
Research Capacity Funding Technology Assessment programme for Research linked to Mammo50 trial support | University Hospitals Coventry and Warwickshire NHS Trust | 01 Jan 2014 | 31 Dec 2016 |
Second Recosting for extension of the Persephone HTA Trial | National Institute for Health Research (DoH) | 01 Jul 2013 | 30 Jun 2016 |
OPTIMA Launch Meeting | Nanostring Technologies | 01 Oct 2015 | 31 Dec 2015 |
Lugols Iodine in Head and Neck Cancer Surgery: A multi-centre randomised controlled trial assessing the effectiveness of Lugols Iodine - 15mth extension to the LIHNCS study. | Cancer Research UK | 01 Oct 2014 | 31 Dec 2015 |
OPTIMA extra funds | National Institute for Health Research (DoH) | 01 May 2015 | 31 Oct 2015 |
BAYER - Investigator led research proposal: *SELECT-D* Duration of anticoagulation therapy in SELECTeD patients with advanced cancer at risk of recurrence of venous thromboembolism - | Bayer plc | 01 Oct 2012 | 30 Sept 2015 |
Support for WMS Clinical Trials Unit Facility | Wolfson Foundation | 01 Jul 2007 | 30 Jun 2015 |
ARTEMIS Pre-operative Avastin with neo-adjuvant chemotherapy Year 6 extension | Cancer Research UK | 01 May 2014 | 30 Apr 2015 |
PET-NECK Extension. | National Institute for Health Research (DoH) | 01 Apr 2013 | 31 Mar 2015 |
TEAMM (HTA via Bham) Tackling Early Morbidity in Myeloma: Assessing the benefit of Antibiotic Prophylaxis and its effect on Healthcare Associated Infections | National Institute for Health Research (DoH) | 01 Jan 2010 | 31 Dec 2014 |
Educational Grant towards randomisation costs for CAB B trial (led by University Hospital Birmingham) | Sanofi-Aventis | 13 Dec 2012 | 12 Dec 2014 |
Improving breast cancer detection rates through understanding and modelling the patterns of radiologist performance | Breast Cancer Campaign | 01 Oct 2011 | 30 Sept 2014 |
Supplement for year two of De-ESCALaTE-HPV trial. Award RMRCT0058, original proposal 28097 | Cancer Research UK | 01 Sept 2013 | 31 Aug 2014 |
CRUK/11/043: De-ESCALaTE-HPV - year 3 | Cancer Research UK | 01 Sept 2013 | 31 Aug 2014 |
Neo Escape funding for data manager | University Hospitals Coventry and Warwickshire NHS Trust | 01 Apr 2013 | 31 Mar 2014 |
CRUK:via Bradford LUGOLS | Cancer Research UK | 01 Apr 2010 | 31 Mar 2014 |
Variation: ATRemis:Avastin Randomised Trial with neo-adjuvant chemotherapy for patients with early HER2 negative breast cancer | Cancer Research UK | 01 Jan 2010 | 31 Dec 2013 |
ARTemis: Avastin Randomised Trial with neo-adjuvent cheMotherapy for patients with early HER 2 negatIve breaSt cancer | Cancer Research UK | 01 Dec 2008 | 30 Nov 2013 |
HTA FULL proposal: OPTIMA (Pilot Study) | National Institute for Health Research (DoH) | 01 Sept 2012 | 31 Aug 2013 |
3 month extention of the Persephone HTA Trial | National Institute for Health Research (DoH) | 01 Apr 2013 | 30 Jun 2013 |
Supplement from Cambridge University - PERSEPHONE Trial | NHS Health Technology Assessment (HTA) | 20 Apr 2011 | 31 Mar 2013 |
Persephone - Adjuvant: Duration of Adjuvant Trastuzumab Study with Chemotherapy in Early Breast Cancer: Six Versus Twelve Months | NHS Health Technology Assessment (HTA) | 01 Apr 2007 | 31 Mar 2013 |
Positron emission tomography - CT scan (pet-CT) guided watch and wait policy versus planned neck dissection for locally advanced (N2/N3) nodal metastases in patient with head neck squamous carcinoma treated with radical chemoradiotherapy. | NHS Health Technology Assessment (HTA) | 01 Apr 2007 | 31 Mar 2013 |
Educational Conference Sponsorship agreement for Optima launch event | GE Healthcare | 22 Jan 2013 | 28 Feb 2013 |
MRC DPFS via Queens University Belfast: Identifying markers of response to anti-oestrogen therapy | MRC | 01 Feb 2011 | 31 Jan 2013 |
COUGAR 2 Extension - Andrea Marshall | Cancer Research UK | 01 Nov 2010 | 31 Oct 2012 |
West Mids SHA Research Training Fellowship:How does contemporary health care meet the needs of those living with a poor prognostic cancer and does it need improving? | West Midlands Strategic Health Authority | 01 Oct 2009 | 30 Sept 2012 |
Characterisation of cardiac changes before and after kidney transplantation using cardiopulmonary exercise testing echocardiograhpy | University Hospitals Coventry and Warwickshire NHS Trust | 01 Aug 2009 | 30 Sept 2012 |
Statistical Analysis Agreement for ARTEMIS | Cancer Research UK | 01 Jan 2009 | 30 Jun 2011 |
AVAST-M: Randomised Trial Evaluating the VEGF Inhibitor, Bevacinumab (Avastin), as Adjuvant Therapy Following Resection of AJCC Stage 11B (T4aNOMO), IIC (TB4NOMO) and III (TxN1-2MO) Melanoma | University of Cambridge | 01 Aug 2006 | 31 Jul 2010 |
COUGAR-2: A Phase III Randomised Controlled Trial of Docetaxel Versus Active Symptom Control as Second Line Treatment in Advanced Gastric Cancer | Cancer Research UK | 01 Jun 2007 | 31 May 2010 |
Neat Science - TOPO | University of Edinburgh | 07 Jul 2008 | 06 Jul 2009 |
Neo-Tango Statistical Analysis | University of Cambridge | 01 Apr 2008 | 31 Mar 2009 |
Proof concept study for use of topical oral cyclo-oxygenase inhibitors (cox-1) mouthwash. | Cancer Research UK | 01 Apr 2007 | 31 Mar 2009 |
Neo-tango statistical analysis | Cancer Research UK | 01 Mar 2007 | 28 Feb 2009 |
MK 966,201 ViP data analysis. | Merck & Co Inc | 19 Jun 2006 | 31 Dec 2007 |
Travel Award for Improving Data Collection for Statistics of Cancer Incidence, Management, Mortality and Survival in the UK | Cancer Research UK | 01 Feb 2007 | 30 Nov 2007 |
Improving Ethnic Data Collection for Statistics of Cancer Incidence, Management, Mortality and Survival in the UK. | Cancer Research UK | 01 Sept 2006 | 30 Jun 2007 |
CRUK Travel Award for R Millwood - Society of Clinical Trials Meeting May 2006 | Cancer Research UK | 01 Sept 2006 | 31 May 2007 |
Reimbursement of secondment funds for Miss Andrea Burton to work on project at Oxford | Cancer Research UK | 01 Oct 2005 | 30 Sept 2006 |